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Abstract:  1 
Background: Coagulation proteases play an important role in atherogenesis. Accordingly, 2 
anticoagulants can induce regression in animal models of atherosclerosis, but exploiting this 3 
clinically has been limited by major bleeding events that occur after systemic anticoagulation. 4 
Here we test a novel thrombin inhibitor, PTL060, that comprises hirulog covalently linked to a 5 
synthetic myristoyl electrostatic switch to tether it to cell membranes. 6 
Methods and Results: ApoE-/- mice, fed either chow or high fat diets were used. 7 
Transplantation of congenic aortic segments was used to demonstrate the impact of 8 
expressing anticoagulants on endothelium. PTL060, parental hirulog or controls were tested 9 
to assess suppression of vessel wall chemokine gradients, impact on plaque development 10 
and regression of existing plaques. Adoptive transfer of labelled CD11b positive cells was 11 
used to assess recruitment of monocytes and inform on how PTL060 influenced monocyte 12 
phenotype. 13 
Transgenic expression of anticoagulant fusion proteins based on TFPI or hirudin on EC led 14 
to complete suppression of MIF and CCL2 expression throughout the vessel wall and 15 
segments of aorta transplanted into ApoE-/- mice did not develop atherosclerosis. A single IV 16 
injection of PTL060, but not parental (unmanipulated) hirulog inhibited the same chemokines 17 
for >1 week and atheroma formation was reduced by >50% compared to controls when 18 
assessed 4 weeks later. Mice had prolonged bleeding times for only 1/7th of the time that 19 
PTL060 was biologically active. Repeated weekly injections of PTL060 but not parental 20 
hirulog caused regression of atheroma in ApoE-/- mice fed either chow or high fat diets. 21 
Mechanistically, 100% of circulating monocytes quickly became coated with PTL060 after the 22 
first dose, following which >70% of CCR2+ monocytes recruited into plaques expressed 23 
CCR7, ABCA1 and IL-10, a phenotype associated with regression, compared to <20% of 24 
CCR2+ recruits in control mice.. Multiple doses caused a significant reduction in the number 25 
of monocytes recruited, and a switch to recruitment of CCR2-negative cells, the majority of 26 
which (>90%) had a similar regression-associated phenotype. The impact of PTL060 on 27 
 4 
circulating monocytes appeared dominant, as regression equivalent to that induced by IV 1 
PTL060 was induced by adoptive transfer of CD11b+ cells pre-coated with PTL060. 2 
Conclusions: PTL060, a novel tethered direct thrombin inhibitor causes regression of 3 
atherosclerosis in ApoE-/- mice, via an effect at the endothelial surface but also through a 4 
direct effect on monocytes, causing differentiation into macrophages capable of plaque 5 
regression. Covalent linkage of a myristoyl electrostatic switch onto hirulog uncouples the 6 
pharmacodynamic effects on haemostasis and atherosclerosis, such that regression is 7 
accompanied by only transient anticoagulation.    8 
 9 
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Clinical Perspective 1 
• What is new: 2 
• We have developed a novel direct anti-thrombin inhibitor specifically to target inflammatory 3 
processes, by covalently linking a synthetic myristoyl electrostatic switch (for cell-membrane 4 
localisation) to hirulog.  5 
• Upon IV injection, it has the same anti-coagulant profile as equimolar hirulog, but the 6 
membrane-localising component promotes prolonged localisation on circulating leukocytes 7 
and vascular endothelium. 8 
• This novel therapeutic induces regression of atherosclerosis in ApoE-/- mice after weekly IV 9 
dosing, by mechanisms that are dependent on this pattern of prolonged binding to cells 10 
within the vasculature, 11 
• Throughout treatment, mice are systemically anticoagulated for only 1 day out of 7. 12 
 13 
Clinical Implications: 14 
• For the first time we have defined a way to uncouple the effects of hirulog on haemostasis 15 
from its effects on atheroma formation.   16 
• Alongside our descriptions of the mechanisms through which atheroma regression is 17 
induced, our findings should provide a foundation for the development of strategies to safely 18 
harness the powerful anti-inflammatory effects of therapeutics that inhibit coagulation 19 
proteases, without adverse events related to bleeding. 20 
  21 
 6 
Non-standard Abbreviations and Acronyms 1 
 2 
ABCA1 - ATP-binding cassette transporter – 1 3 
-TFPI-Tg – a strain of transgenic mice expressing membrane tethered hTFPI under 4 
smooth muscle actin  promoter 5 
ApoE – apolipoprotein E 6 
BL/6 – C57BL/6 mice 7 
CCL-2 - chemokine (C-C motif) ligand 2  8 
CCR2 - C-C chemokine receptor type 2 9 
CCR7  - C-C chemokine receptor type 7 10 
CD31-Hir-Tg – a strain of transgenic mice expressing membrane tethered hirudin 11 
under CD31 promoter 12 
EC – endothelial cell 13 
HFD – high fat diet 14 
HLL – chemical modified hirulog 15 
hTFPI – human tissue factor pathway inhibitor 16 
iNOS – inducible nitric oxide synthase 17 
LDL – low desnity lipoprotein 18 
MIF – macrophage migration inhoibotory factor 19 
MCSF – macrophage colony stimulating factor 20 
ORO – Oil red O 21 
PAR – protease activated receptor 22 
PKH2 – green fluorescent dye taken up by phagocytic cells 23 
PKH26 - red fluorescent dye taken up by phagocytic cells 24 
PTL060 – the new tailed direct anti-thrombin 25 
SMC – smooth muscle cell 26 
TF – tissue factor 27 
  28 
 7 
Introduction 1 
Atherosclerosis, is a chronic inflammatory disease that causes coronary artery, peripheral 2 
vascular and cerebrovascular disease. It is a major cause of death in the Western world. 3 
Important early steps in atherogenesis, in the context of a high lipid microenvironment 4 
include secretion of chemokines such as CCL-2 and macrophage migration inhibitory factor 5 
(MIF) 1, by activated endothelial cells (ECs) and smooth muscle cells (SMCs) 2, 3 . These 6 
promote infiltration of monocytes into the subendothelial space, where they become 7 
macrophages and take up very low-density lipoprotein and low-density lipoprotein (LDL) to 8 
become foam cells, initiating the process of atheroma formation.  9 
Coagulation proteases, such as thrombin, signal though protease activated receptors (PAR) 10 
as well as catalysing fibrin formation and are known to play a role in this process. Increased 11 
activity of tissue factor (TF), the 47-Kd cell membrane-bound glycoprotein that initiates the 12 
serine protease cascade, is seen in the neointima and underlying media of atherosclerotic 13 
plaques 4-6 and TF is expressed by EC 7, monocytes/macrophages 8 and SMC 9.  14 
In previous work, we crossed a strain of transgenic mice expressing a membrane-tethered 15 
human Tissue Factor Pathway Inhibitor (hTFPI) fusion protein on -smooth muscle actin 16 
(SMA)+ cells (called -TFPI-Tg mice) 10 with Apolipoprotein E–deficient (ApoE-/-) mice to 17 
generate a new strain (called ApX4). These mice were resistant to atheroma formation 11. In 18 
dissecting the mechanism of resistance, we showed that TF expression by SMC was 19 
necessary to generate MIF, via generation of thrombin and signalling primarily through PAR-20 
1. Inhibition of either the TF, thrombin mediated PAR-1 signalling or MIF secretion prevented 21 
atherosclerosis in mice fed either a high fat diet (HFD) or a regular chow-based diet.   22 
One of the observations from that study was that MIF continued to be secreted by EC in 23 
ApX4 mice fed a HFD, beneath which small atherosclerotic plaques developed 11. This 24 
suggested that targeting SMC with hTFPI was not completely efficient at inhibiting atheroma. 25 
In this new study, we explored how transgenically-expressed tethered anticoagulants on EC 26 
impacted on atherosclerosis development, and assessed the translational potential of a novel 27 
thrombin inhibitor containing the potent peptide hirulog (a direct thrombin inhibitor), that has 28 
 8 
been chemically modified (HLL) to accept a lipid membrane-binding anchor or ‘cytotopic’ tail. 1 
This new compound is called PTL060 (thrombalexin-3). PTL060 has previously been 2 
localised within organs before transplantation to successfully inhibit thrombosis and rejection 3 
in several models 12-14.  In the process we describe an unpredicted impact of PTL060 on the 4 
phenotype of monocytes recruited into atherosclerotic plaques, by two interrelated pathways, 5 
one of which occurs by virtue of its ability to tether directly to monocytes. We also provide a 6 
mechanistic insight into the role that thrombin appears to play in driving plaque progression, 7 
as evidenced by the regression seen when PTL060 is administered systemically.   8 
 9 
Methods 1 
The data that support the findings of this study are available from the corresponding author 2 
upon reasonable request. 3 
 4 
Mice and in vivo procedures 5 
C57BL/6J (BL/6) mice were purchased from Harlan UK Ltd (Bicester, UK) and ApoE-/- mice 6 
were from the Jackson Laboratory (Bar Harbor, Maine 04609, USA). CD31-TFPI -Tg and 7 
CD31-Hir-Tg15 mice were bred in house. Mice were housed in a temperature-controlled 8 
Specific Pathogen-Free environment at 22–24°C and all animal surgical protocols, animal 9 
experiments and care were approved by the local ethics committee and the UK Home Office. 10 
To assess the distribution of PTL060, male BL/6 mice weighing 25 – 28g (n=6 per group) 11 
were injected IV through a tail vein with either PTL060 (10µg/g in 100 µl saline), equimolar 12 
HLL (5µg/g) or saline. At 5, 30 minutes and 2, 4, 6, 24 and 48 hours mice were sacrificed to 13 
collect citrated whole blood for separation into cells and plasma and to harvest aortas for 14 
immunofluorescence analysis.  15 
Bleeding times were assessed as previously described 15. Briefly, mice were anesthetized 16 
and placed in a restrainer (Becton Dickinson), before a distal 3-mm segment of tail was 17 
severed with a razor blade. The tail was immediately immersed in 0.9% saline at 37°C. 18 
Bleeding time was defined as the time required for bleeding to stop. Experiments were 19 
terminated at this time or at 20 minutes. 20 
For all atherosclerosis work, male ApoE-/- mice, from the age of 6-weeks, were fed with a 21 
HFD consisting 35 kcal% fat, 1.25% cholesterol, and 0.5% cholic acid (Special Diet Services, 22 
Essex UK). Aortas were transplanted 2 weeks after starting the HFD, using a sleeve 23 
anastomosis technique described previously 11.  Briefly, a 5mm of the segment of the 24 
infrarenal donor aorta, flushed with 300 µl of saline containing 50U of heparin, was 25 
transplanted into ApoE-/- recipient abdomen aortas (N=6 per group). Blood flow was 26 
confirmed by direct inspection after removal of the clamps. Mice were fed a HFD for 6-12 27 
weeks post-transplantation before the experiment was terminated (Suppl fig 1A). To assess 28 
 10 
prevention of atheroma, mice (n=6 per group) received a single injection of PTL060 or 1 
controls by tail vein, and the experiments terminated 1-3 weeks later (Suppl fig 1B). For 2 
regression experiments, baseline groups (n=6) were fed a HFD to the age of 22 weeks 3 
before the mice were sacrificed. Experimental or control groups (n=3-6 per group) received 4 
weekly injections by tail vein for 3-6 weeks, beginning at age of 22 weeks before the 5 
experiments were terminated when mice were 25-28 weeks old (Suppl fig 1C). 6 
 7 
Cell isolation and labelling. 8 
Leukocytes were isolated from the blood of mice aged 8-10 weeks, using anti-CD11b 9 
MicroBeads (Miltenyi Biotec Ltd, Surrey, UK) according to manufacturers’ instructions. For 10 
cell labelling, 2x107 CD11b+ cells were incubated with 4x10-6 M of either PKH26 or PKH2 11 
fluorescent dyes (Sigma, UK) for 5 minutes at 25⁰C according to manufacturers’ protocols, 12 
with the reaction stopped using 1% BSA in PBS followed by three washes. Each recipient 13 
mouse received 0.5x106 cells by IV injection; in some experiments, the cells were incubated 14 
with PTL060 (100M in 0.5mls) or equimolar controls for 30 minutes at room temperature 15 
and washed three times before immediate injection. Cell viability was confirmed immediately 16 
prior to transfer by trypan blue extraction. 17 
For specific viability assays, murine bone marrow cells were incubated for 5 days in 6 well 18 
plates, counted and re-seeded at 2x105 cells/ml in 24 well plates with 25ng/ml MCSF. After 1 19 
day, media was replaced with new DMEM/FCS containing different concentrations of 20 
PTL060 (or a fixed volume of control PBS), and incubated for 30-120 minutes, before 21 
assessment by flow cytometry (see below).  22 
 23 
Histological analysis  24 
Atherosclerotic lesions were evaluated as previously described 11. Simply, the entire length of 25 
the aorta was perfused with PBS, dissected using a dissecting microscope, longitudinally 26 
opened and stained with Oil Red O (ORO) solution (Sigma, UK) for 30 minutes, before being 27 
photographed with a digital camera (DSC-W320, Sony, Japan). The total aortic area and 28 
 11 
lesional area were measured by using Image J. Aortas from every animal were assessed. To 1 
assess lesions in the aortic sinus, hearts were embedded in paraffin, sectioned through the 2 
aortic root and incubated with elastin/van Gieson stain using the AccustainTM Elastin Stain 3 
kit (Sigma). Sections were examined on an Olympus U-ULH optical microscope (Olympus 4 
Optical Co. Ltd, Tokyo, Japan). Atheromatous lesional and total aortic root area was 5 
determined using Image-Pro Plus TM software version 4.0 (Media Cybernetics, Silver Spring, 6 
USA). At least three random sections were examined from each mouse in all groups.  7 
Immunohistology of frozen cross sections were prepared and examined as previously 8 
described 11.  Briefly, isolated tissues were snap-frozen and embedded in OCT compound 9 
(VWR International, Dorset, UK), sectioned at 5µm thickness and fixed in methanol at –20°C. 10 
Frozen sections were immersed in 1% bovine serum albumin–phosphate-buffered saline 11 
(BSA-PBS) for 30 minutes and then incubated overnight at 4°C with one or more of the 12 
following antibodies: rabbit polyclonal antibody to CD68, iNOs, CD206, TNFα, MIF, CCR7 13 
ABCA1 (all from Abcam, Cambridge, UK), or hirudin (Biobyt, Cambridge, UK) or CCL2 14 
(Lifespan BioScience, Inc., WA 98121, USA); goat polyclonal antibody to CD31 (Santa Cruz 15 
Biotechnology, Texas 75220, USA); rat anti-mouse CD68, CD11b (Serotec, Oxford, United 16 
Kingdom), CD31, IFNγ (BD Bioscience Pharmingen, Oxford, United Kingdom), Ly-6G 17 
(BioLegend, London, UK), IL-10 (Abcam) or biotinylated anti-HLL (RICS-2)14; mouse anti-18 
CCR2 (Abcam). The following were used as isotype controls; goat anti-rat antibodies to 19 
IgG2a, IgG2b (BD Bioscience, Berkshire, UK) and polyclonal rabbit IgG (Abcam). The 20 
following anti-IgG FITC or TRITC-conjugated antibodies were used: sheep anti-mouse, rabbit 21 
anti-rat, goat anti-rabbit and rabbit anti-goat (all from Sigma). Fluorescein-conjugated 22 
streptavidin (Jackson Immunoresearch, Cambridge, UK) was used to detect RICS-2. Stained 23 
sections were mounted in Vectashield with DAPI (Vector Laboratories Inc, CA USA). 24 
Sections were directly captured and examined by a Leica DMIRBE confocal microscope 25 
(Leica, Wetzlar, Germany) equipped with Leica digital camera AG and a confocal laser 26 
scanning system with excitation lines at 405, 488, 543, and 560 nm at magnifications 27 
10x/0.40CS and 20x/0.70IMM (Leica, Planapo, Wetzlar, Germany). Images were processed 28 
 12 
using Leica-TCS-NT software associated with the Leica confocal microscope. All 1 
immunohistochemistry was performed at 220 C. Quantification of staining was achieved by 2 
expressing the area of positive staining as a ratio of the total lesion area, calculated using 3 
Image-Pro Plus TM, version 4.0. All quantification was performed by members of the team 4 
blinded to the identity of the sections. For estimations of positive stained area, average 5 
measurements were derived from examination of at least six random sections from each 6 
tissue sample. 7 
To detect macrophage-derived foam cells, frozen sections of aortic sinus were analysed by a 8 
combination of ORO staining and CD68 immunostaining. Sections were incubated with rat 9 
anti-mouse CD68 antibody (overnight at 4°C) and goat anti-rat antibody (1 hour at room 10 
temperature) before staining with filtered ORO solution (0.5% in propylene glycol, Sigma) for 11 
15 minutes at room temperature.  12 
 13 
Plasma assays.  14 
Anticoagulated whole blood (EDTA 30mM pH8) was separated into plasma and cells by 15 
centrifugation (14,000g for 10 mins).  Plasma TNFα, IFN-, MIF and CCL2 were detected 16 
using separate specific ELISA kits (R&D Systems, Abingdon, UK) according to the 17 
manufacturers’ instructions.  Total cholesterol, high-density lipoprotein and low-density 18 
lipoprotein were determined using kits from Cell Biolabs, and Tryglycerides with a kit from 19 
Abcam, (both Cambridge, UK) according to the manufacturer’s protocol. Data were derived 20 
from triplicate analysis of each sample. 21 
Thrombin clotting times were measured in 3.2% trisodium citrated plasma according to the 22 
protocol of Ignjatovic 16. Briefly, 100l mouse plasma was incubated with 2.5U of human 23 
thrombin in a total volume of 300µl (Enzyme Research Laboratories (ERL), Swansea, UK) at 24 
37°C, and the time for a clot to form was measured (n=6 per group). For some experiments 25 
plasma was further centrifuged (20,000g for 10 mins) to minimise the presence of 26 
extracellular vesicles. 27 
 28 
 13 
Flow cytometry 1 
The cells obtained from whole blood were washed twice in PBS with 2% FCS before staining 2 
with either anti-CD11b-FITC (Abcam) or anti-CD41-FITC (eBioscience) with biotinylated 3 
RICS2 followed by Streptavidin-PE (Bio-rad). Cells were then washed twice before analysis 4 
on a BD FACSCALIBUR with CellQuest Pro software. Erythrocytes were identified by 5 
forward/side scatter profile.  6 
For viability assays, cells were washed twice with PBS and then incubated with Fixable 7 
LIVE/DEAD Near-IR fluorescent reactive dye (Thermofisher Scientific, Paisley, Renfrewshire, 8 
UK) for 30 minutes at 4 °C. Cells were washed, fixed for 15 minutes in 1% paraformaldehye, 9 
then washed with PBS-5% FCS and stored at 4 °C before acquisition and analysis within 24 10 
hours on an LSRII/Fortessa flow cytometer at the BRC Flow Cytometry Laboratory, King’s 11 
College London with Flowjo software (Treestar Inc). Macrophages identified by forward/side 12 
scatter profile. 13 
 14 
SMC-MIF/CCL2 release assay in vitro  15 
SMCs, cultured as previously described 11 and seeded at a density of 1×106 cells/well of a 16 
24-well plate were serum-starved for 24 hours before addition of PTL060 (100M) for 1 hour, 17 
followed by PAR agonists or antagonists (all from ERL) for 12 hours, followed by thrombin 18 
10nM or active site inhibited thrombin (ERL) for 48 hours, before collection of supernatants. 19 
Chemokines were measured by ELISA according to the manufacturers’ instructions (R&D 20 
systems, Abingdon, UK). Data were derived from triplicate analysis of each sample. 21 
 22 
Statistical Analysis 23 
Statistical analysis was performed with GraphPad Prism 8 software. Comparison of a single 24 
factor between two groups is by unpaired student’s t test. One or Two way analysis of 25 
variances (ANOVA) was used as appropriate when making comparisons of ≥ two factors or 26 
between multiple groups. Data are presented either as mean ± SEM or as box plots with 27 
 14 
median and interquartile range. The value of P that was considered significant was adjusted 1 
for multiple comparisons and listed in figure legends.  2 
 3 
  4 
 15 
Results. 1 
Anticoagulants transgenically localised to EC completely inhibit vessel wall expression of 2 
chemokines and prevent formation of atheroma. 3 
To assess the impact of expressing hTFPI fusion protein on EC alone, we used the congenic 4 
aortic transplant model previously described 11, and compared the extent of atheroma 5 
development in transplanted aortas from CD31-TFPI-Tg mice (expressing hTFPI transgene 6 
on EC 15) and BL/6 mice. The recipients were 8-week old ApoE-/- mice fed a HFD for 2 7 
weeks prior to the transplant, and the experiment was terminated 6 weeks after the 8 
transplant (suppl Fig 1). In the aortic transplants from CD31-TFPI-Tg mice, MIF expression 9 
was absent through the entire wall of the transplanted vessel, not just the EC (Fig 1 A&B) 10 
and atheroma formation was significantly attenuated in the transplanted donor segment (Fig 11 
1 F&H). In contrast and as previously reported, control BL/6 aortic transplants developed 12 
exaggerated lesions, associated with MIF expression in all layers of the vascular wall (Fig 1 13 
E, G, H &J). The atherosclerosis that developed in the recipient aortas was independent of 14 
the type of donor aorta transplanted (Fig 1 G, H &I). 15 
Next we transplanted aortas from a second transgenic strain (CD31-Hir-Tg) 15, expressing a 16 
tethered hirudin fusion protein on EC (suppl Fig 1), and these showed similar suppression of 17 
MIF expression throughout the vessel wall and were similarly resistant to atheroma 18 
developmenta (Fig 1C, D, K-O), indicating that inhibition of thrombin and TF on EC was 19 
functionally equivalent, entirely consistent with our previously published results 11. In addition 20 
to MIF, CCL-2 expression was completely suppressed throughout the vessel walls of 21 
transplants from both transgenic strains (suppl Fig 2). This data indicates that inhibiting 22 
thrombin generation (by TFPI) or the enzymatic activity of thrombin (by hirudin) on transgenic 23 
EC after transplantation into ApoE-/- mice completely suppresses MIF and CCL-2 expression 24 
throughout the entire vascular wall and prevents atheroma formation. 25 
 26 
                                                        
a NB in this series of experiments, the time that aortas were left in situ was extended to 12 weeks post-
transplantation. 
 16 
IV injection of PTL060, a novel tethered therapeutic anti-thrombin. 1 
After IV administration of PTL060 into BL/6 mice, linear deposition of the anticoagulant 2 
moiety could be found on the luminal surface of the aorta mice several hours later (fig 2A). 3 
This pattern of staining was never seen after injection of parental (untailed) HLL (fig 2B). 4 
PTL060 also very quickly attached to the lipid membranes of circulating erythrocytes, 5 
leukocytes and platelets (fig 2C-E), maintaining stable levels of binding between 2-6 hours 6 
post-injection, before reducing between 24-48 hours post injection.  No binding was ever 7 
seen after injection of HLL. In vitro viability assays, performed by incubating bone marrow-8 
derived macrophages with increasing concentrations of PTL060 for 30-120 minutes 9 
confirmed no evidence of toxicity (suppl table 1). 10 
Thrombin clotting times of citrated plasma were prolonged for > 6 hours post injection of 11 
PTL060, indicating the presence of a thrombin inhibitor, and these were not statistically 12 
different to thrombin clotting times after injection of an equimolar amount of HLL (fig 2F&G). 13 
This was associated with prolonged tail bleeding times (fig 2H) lasting for approximately 24 14 
hours, with bleeding times in PTL060-treated mice not statistically different from those 15 
recorded in mice given an equimolar concentration of HLL (fig 2H). Thus, IV injection of 16 
PTL060 resulted in rapid uptake onto the membranes of circulating cells and platelets, with 17 
detectable deposition on EC a few hours later. Despite this, the thrombin inhibitory activity 18 
detected in plasma was indistinguishable from that seen after injection of the HLL, and mice 19 
showed prolonged bleeding for 24 hours.  20 
 21 
We assessed the differential impact of PTL060 and HLL on expression of MIF by the 22 
vasculature, as a biomarker of potential efficacy at suppressing atheroma formation. A single 23 
IV injection of PTL060 was accompanied by complete suppression of MIF expression 24 
throughout the vessel wall for almost 1-week (suppl fig 2D; fig 3A), which was dose 25 
dependent (fig 3D). This effect was never seen in controls given saline (suppl fig 2E) or in 26 
mice administered an equimolar dose of HLL (fig 3D). This prolonged biological effect of 27 
PTL060 is consistent with our previous demonstration that, once bound to endothelium, it 28 
 17 
remains detectable for >4 days 14. In vitro experiments confirmed that thrombin-mediated 1 
chemokine expression was primarily via PAR-1 and that PTL060 completely inhibited this 2 
(suppl fig 3). 3 
These data indicate that equimolar doses of PTL060 and HLL induce similar degrees of 4 
systemic thrombin inhibition lasting approximately 24 hours, but only PTL060 promotes 5 
prolonged suppression of MIF expression by vessel wall cells. 6 
 7 
Impact of PTL060 on atherosclerosis 8 
A single injection of PTL060 caused significant inhibition of atheroma formation in ApoE-/- 9 
mice fed a HFD for two weeks prior to, and four weeks after the injection (Fig 3A, B&C). This 10 
effect was dose dependent (fig 3D, E-H), and only occurred with doses that inhibited MIF 11 
expression for up to 1 week (fig 3A, D; suppl fig 2D). It was not seen in mice administered 12 
equimolar doses of HLL (fig 3D, H). Thus, a membrane tethered thrombin inhibitor can 13 
replicate the impact of a transgenically expressed membrane tethered thrombin inhibitor by 14 
suppressing the development of atherosclerosis. 15 
To assess the impact of PTL060 on established atheroma, 6-week old ApoE-/- mice were fed 16 
a HFD until the age of 22 weeks, before receiving IV injections of saline, HLL, control 17 
cytotopic tail compound or PTL060, weekly for a further 6 weeks. PTL060 caused a reduction 18 
in atheroma burden, when measured either by en face analysis or by cross sectional analysis 19 
of the aortic root (fig 4A-R), an effect not seen after weekly injections of any of the controls, 20 
including HLL at equimolar doses (fig 4 A-R). This was associated with a reduction in the 21 
area of plaque occupied by lipids, as shown by Oil-red O staining (fig 4S&U), as well as a 22 
reduction in the CD68+ cells co-localising with lipid (fig 4T&U), indicating a significant 23 
reduction in the number of foam cells within the plaques. This effect of PTL060 was evident 24 
even compared to baseline mice analysed at week 16 prior to any treatment, indicating that 25 
disease regression was induced by PTL060. All the effects of PTL060 were seen without any 26 
discernible impact on body mass or circulating lipid concentrations (table 1).  27 
 18 
PTL060 also significantly reduced atheroma burden after administration to ApoE-/- mice fed 1 
a normal chow diet, weekly from the age of 28 weeks for 6 weeks (fig 4V-Z). Under both HFD 2 
and Chow dietary conditions, administration of PTL060 was accompanied by significant 3 
reductions in plasma levels of TNF, IFN, MIF and CCL2 (suppl fig 4), compared to the 4 
appropriate controls.   5 
 6 
The phenotype of regressing plaques after PTL060 treatment  7 
Atheromatous plaques in ApoE-/- mice fed a HFD from 6-22 weeks of age (baseline) 8 
contained a significant number of CD68+ cells (monocytes/macrophages), occupying 9 
approximately 45% of plaque area (fig 5A,F). Compared to control animals injected with 10 
either saline or HLL (fig 5B-G), weekly injections of PTL060 reduced the proportion of plaque 11 
area occupied by CD68+ cells to below 20% (fig 5D,F) with an associated increase in the 12 
proportion of plaque cells that were CD68-negative (fig 5G). The proportion of plaque area 13 
staining for MIF reduced from >60% at baseline (fig 5A, E) to <20% (fig 5 D,E) though the 14 
proportion of CD68+ and CD68-neg cells that expressed MIF was not altered (fig 5F,G). 15 
These data indicate that PTL060 induced a shift in plaque cell composition, from 16 
predominantly CD68+ cells in control mice to predominantly CD68-negative cells after 17 
PTL060 treatment, in association with a marked reduction in vessel wall MIF expression. 18 
Plaques developing in mice fed a HFD between 6-22 weeks were almost devoid of cells 19 
expressing the chemokine receptor CCR7 (fig 5H,K) or the cholesterol efflux regulator ATP-20 
binding cassette transporter molecule ABCA1 (fig 5O,S), with <10% of plaque cells co-21 
expressing these molecules (fig 5I,J & T,U). Six weeks of treatment with weekly PTL060 from 22 
weeks 22-28 caused significant increases in the proportion of plaque area occupied by cells 23 
expressing CCR7 and ABCA1 (fig 5 H,N,R,S) and almost all of these were CD68+ cells (fig 5 24 
I,N,R,T), compared to control saline-treated mice and in contrast to mice treated with weekly 25 
injections of HLL, in whom expression of both CCR7 and ABCA1 was not statistically 26 
different to that seen at baseline (fig 5H-M & O-U). 27 
 19 
In parallel, little IL-10 staining was seen within the plaques of any of the control animals 1 
(suppl fig 5A,B), and <2% of plaque-infiltrating CD68+ cells co-expressed IL-10 (suppl fig 2 
5C), whereas almost all plaque infiltrating CD68+ cells expressed IFN (suppl fig 5E, G)) and 3 
TNF (suppl fig 5I,K,) and 15-20% of plaque CD68-negative cells expressed these two pro-4 
inflammatory cytokines (supp fig 5H,L). After six weeks of PTL060, 10-15% of plaque area 5 
stained for IL-10 (suppl fig 5A, B), including 60% of the plaque-infiltrating CD68+ cells (suppl 6 
fig 5C), and approximately 10% of CD68-negative cells (suppl fig 5D). There was a marked 7 
reduction in both the proportion of plaque area (suppl fig 5E,F, I,J) and the proportion of 8 
CD68+ cells (suppl fig 5G,K) staining for INF and TNFα, compared to control saline-treated 9 
mice and in contrast to mice treated with weekly injections of HLL, in whom no reductions 10 
were seen. Similar dichotomous patterns of staining were seen for the macrophage 11 
polarisation markers iNOS (suppl figure 6A-D) and CD206 (suppl fig 6E-H), with staining for 12 
the former suppressed in both CD68+ and CD68-negative cells, but staining of the latter 13 
enhanced in CD68+ cells, by weekly injections of PTL060.  14 
Thus, six weeks of weekly PTL060 injections promoted a significant reduction in plaque 15 
CD68+ cells and a significant shift in their phenotype, towards a phenotype that has 16 
previously been associated with plaque regression (CCR7+, ABCA1+, IFN-, IL-10+, iNOS-, 17 
CD206+). 18 
 19 
Mechanism of regression: Impact of thrombin inhibitor tethered to the surface of circulating 20 
monocytes. 21 
As shown already, PTL060 rapidly adheres to the surface of circulating leukocytes. To 22 
investigate the impact of this leukocyte-tethered thrombin inhibitor, in isolation to that 23 
tethered by EC or platelets and erythrocytes, we adoptively transferred CD11b+ cells 24 
labelled with the fluorescent dye PKH26 into ApoE-/- mice fed a HFD from weeks 6-22, 25 
before assessing the phenotype of the labelled plaque cells by confocal immunofluorescence 26 
microscopy 48 hours later. To avoid the potential confounding influence of transfer of 27 
 20 
PTL060 from the adoptively transferred cells to vascular membranes, for these experiments 1 
we used CD11b+ cells from CD31-Hir-Tg mice, which express covalently tethered cell 2 
surface hirudin on all monocytes, and compared the impact of labelled BL/6 cells.  3 
At the point of adoptive transfer, MIF was expressed throughout the plaques (fig 6A), and 4 
significant numbers of labelled cells were recruited, such that they occupied 20-25% of 5 
plaque area (fig 6B, C), with no difference in the numbers of BL/6 vs CD31-Hir-Tg cells 6 
recruited (fig 6D). All recruited cells from the Tg strain expressed hirudin (fig 6C). Although 7 
the plaques already contained significant numbers of Ly6G+ granulocytes, occupying 20-8 
25% of plaque area, and although the adoptively transferred CD11b+ populations contained 9 
granulocytes, <1% of the recruited PKH26-labelled cells co-expressed Ly6G (fig 6E-G), 10 
suggesting they were mostly monocytes, and >95% of the labelled cells, from both BL/6 and 11 
CD31-Hir-Tg, expressed CCR2 (fig 6H-J), suggesting they were predominantly Ly6Chi 12 
monocytes. Whereas none of the recruited BL/6 cells expressed ABCA1 or CCR7, the 13 
majority of CD31-Hir-Tg cells recruited to the plaques expressed both these markers (fig 6K-14 
P). In addition, whereas the majority of recruited BL/6 cells expressed IFN and iNOS, these 15 
were expressed by few of the recruited CD31-Hir-Tg cells (suppl fig 7). Instead, a significant 16 
minority of these cells expressed IL-10 and CD206, markers not expressed by labelled BL/6 17 
cells (suppl fig 7). These data illustrate that CCR2+ monocytes recruited to established 18 
plaques are polarised towards a pro-inflammatory M1 phenotype, but that a membrane 19 
tethered anti-thrombin subverts this phenotype towards one that has previously been 20 
associated with plaque regression. This strongly suggests that the shift towards regression, 21 
induced by PTL060, begins immediately post-injection via the influence of cell tethered 22 
PTL060 on the phenotype of CCR2+ monocytes recruited to existing plaques. 23 
 24 
Monocyte recruitment and phenotype after systemic PTL060. 25 
To assess whether PTL060 reduced numbers of monocytes recruited, ApoE-/- mice were fed 26 
a HFD from 6-22 weeks, before administration of weekly PTL060 or saline for 3 weeks to the 27 
age of 25 weeks. PKH2-labelled CD11b cells from BL/6 mice were administered one week 28 
 21 
after the last injection of PTL060 (by which time all PTL060 should have left the circulation 1 
(see Fig 2), and plaques examined 48 hours later by confocal immunofluorescence 2 
microscopy. After 3 weeks treatment with PTL060, there was significant suppression of MIF 3 
expression by vessel wall cells (fig 7A,B), associated with a significant reduction in the 4 
number of adoptively transferred cells recruited to the plaques, such that they occupied only 5 
2% of plaque area compared to 20% in control mice that had received saline (fig 7C). 6 
As at baseline, the monocytes recruited into plaques of saline treated animals were 7 
predominantly CCR2+(fig 7D,F), suggesting they belonged to the Ly6Chi subset. However, 8 
monocytes recruited to plaques in PTL060-treated mice were predominantly CCR2-neg, 9 
suggesting they were predominantly Ly6Clo monocytes (fig 7E,F). Compared to cells 10 
recruited in saline treated mice, the majority of labelled cells recruited into the plaques of 11 
PTL060 mice expressed CCR7 (fig 7G-I) and ABCA1 (fig 7J-L), as well as IL-10 (suppl fig 12 
8A-C) but fewer cells expressed TNF (suppl fig 8D-F) or IFN (suppl fig 8G-I). Therefore, 13 
weekly systemic delivery of PTL060 suppressed vessel wall chemokine production, 14 
significantly reduced the recruitment of adoptively transferred monocytes by >90% compared 15 
to controls and promoted recruitment of CCR2-negative monocytes, which, independently of 16 
any direct binding of PTL060 to their cell surface, had the same phenotype that has already 17 
been associated with plaque regression. 18 
 19 
A thrombin inhibitor on the surface of CD11b+ cells is sufficient to induce regression. 20 
To assess whether tethering of PTL060 to leukocytes alone was sufficient to induce plaque 21 
regression, we fed ApoE-/- mice a HFD from 6-22 weeks, and then adoptively transferred, by 22 
weekly IV injection during weeks 23-28, CD11b+ cells, while continuing the HFD. Control 23 
mice received cells from BL/6 mice incubated, prior to transfer, with either saline or the 24 
cytotopic tail compound only. Experimental mice received BL/6 cells pre-incubated with 25 
PTL060 or, as a positive control, cells from CD31-Hir-Tg mice. The 30 minute incubation with 26 
these compounds had minimal effect on the viability of adoptively transferred cells (suppl 27 
table 2). 28 
 22 
All mice receiving control cells showed progression of atherosclerosis between 23-28 weeks 1 
(fig 8A,B, E,F,I) that was not statistically different in degree to that seen in saline treated 2 
controls described earlier (see Fig 4). In contrast, mice receiving PTL060-treated BL/6 cells 3 
(fig 8C,G,I), or cells from CD31-Hir-Tg mice (fig 8D, H, I) showed regression of plaque area 4 
not statistically different in degree to mice that had been treated with systemic PTL060 (see 5 
Fig 4). The phenotype of regressing plaques in mice given cells from CD31-Hir-Tg mice 6 
strongly resembled those in mice receiving systemic PTL060 (fig 8J). 7 
Taken together with the data from the adoptive transfer of labelled cells, these data indicate 8 
that mechanistically, the impact of systemic PTL060 treatment can be reproduced entirely by 9 
isolating a thrombin inhibitor onto the surface of circulating monocytes, suggesting that 10 
inhibiting thrombin activity on only these cells is sufficient to promote regression. 11 
  12 
 23 
Discussion. 1 
The involvement of coagulation proteases in atherosclerosis and the impact of inhibiting 2 
them has been described by multiple groups in previous studies. For instance, ApoE-/-  mice 3 
made deficient in HCII, a natural thrombin inhibitor 17, or carrying a DNA variant resulting in 4 
defective thrombomodulin-mediated generation of activated protein C 18 develop severe 5 
atheroma, indicating that in this model, endogenous regulators of thrombin act to limit 6 
disease severity. Conversely, factor (F)Xa inhibitors 19, 20 and direct thrombin inhibitors 21-24 7 
prevent atheroma progression and maintain plaque stability  Systemic anticoagulants can 8 
also induce regression of atherosclerosis in ApoE-/- mice. Bea et al used megalatran in 30-9 
week-old animals and showed reduced burden of advanced atheromatous lesions 10 
associated with plaque stability 25. More recently, Posthuma et al 26 reduced atheroma 11 
burden in 22 week old animals by 25% after daily treatment for 6 weeks with clinically 12 
relevant doses of the FXa inhibitor rivaroxaban.  13 
These data from animal models have fed into clinical practice, and the benefit of systemic 14 
anticoagulation in patients with atherosclerosis has been most recently confirmed by the 15 
COMPASS trial, which showed that addition of rivaroxaban to aspirin in patients with stable 16 
atherosclerotic cardiovascular disease led to fewer deaths, strokes and myocardial infarction 17 
27.  Moreover, the PAR-1 antagonist vorapaxar has also been shown to reduce the risk of 18 
myocardial infarction in patients with stable atherosclerosis 28. However, these benefits were 19 
associated with a significant increase in the incidence of major bleeding events; this is the 20 
biggest drawback to using systemic anticoagulants or antiplatelet drugs for non-thrombotic 21 
diseases, as their impact on haemostasis cannot be separated from their clinical efficacy.  22 
The development of thrombalexins built upon a foundation of tethering anti-complement 23 
compounds using a generic tail based on the myristoyl-electrostatic switch 29, 30. We have 24 
demonstrated that several versions of thrombalexin, including PTL060 effectively bind to cell 25 
membranes, maintain potent  thrombin inhibitory activity, and prevent intravascular 26 
thrombosis when infused into rodent 12 or primate kidneys 14 prior to transplantation. Under 27 
these circumstances, PTL060 remains detectable in tissue for several days.  28 
 24 
In this work, we have shown that after IV injection, PTL060 inhibits secretion of vessel wall 1 
chemokines for 1 week and prevents atheroma formation but increases the risk of bleeding 2 
for only 24 hours. Therefore, the addition of the cytotopic tail uncouples the 3 
pharmacodynamics of hirulog’s effects on haemostasis from its effects on atheroma 4 
formation, so that an increased bleeding tendency is seen for only 1/7th of the period 5 
between doses that both prevent plaque formation and induce plaque regression. To our 6 
knowledge, this is the first demonstration of such uncoupling, and represents a significant 7 
advance in understanding the true therapeutic potential of targeting coagulation proteases to 8 
influence inflammatory disease. 9 
 10 
Our interest in this area began with the idea that targeting anticoagulants to cell membranes 11 
would achieve high concentrations in localised environments, such as the endothelium of an 12 
organ transplant, to inhibit vascular thrombosis. We demonstrated proof of concept using 13 
transgenically expressed fusion proteins 15, 31, and in the process showed that inhibiting 14 
thrombin-mediated signalling through protease activated receptors on vessels inhibited local 15 
chemokine gradients, which reduced monocyte recruitment to sites of inflammation, including 16 
after transplantation, and prolonged survival 32.  We then went on to show that thrombin was 17 
similarly involved in chemokine gradient generation in atherosclerosis, such that expression 18 
of a tethered anticoagulant on SMC significantly reduced the development of atheroma in 19 
ApoE-/- mice 11.  In this new work we have confirmed that expression of tethered 20 
anticoagulants on EC is equally efficacious at suppressing vessel wall chemokine expression 21 
by both EC and SMC in ApoE-/- mice and equally effective at preventing atherosclerosis as 22 
expression on SMC. Although there was some variation in the extent of atherosclerosis 23 
development by control ApoE-/- mice fed a HFD for 4-6 weeks across temporally distinct 24 
experiments, one consistent feature was that single doses of PTL060 caused significant 25 
inhibition (≥50%) of atheroma formation compared to controls.  We have not investigated the 26 
mechanism by which targeted thrombin inhibition on EC influences the phenotype of 27 
underlying SMC, but the data are consistent with the known importance of EC / SMC 28 
 25 
interplay for atheroma development 33, and one possibility is that it acts via regulation of 1 
angiopoietin-2 secretion, known to be important in atherosclerosis 34, which we have shown 2 
to be thrombin-dependent in a separate model system 35.  3 
 4 
Our most important finding was that in ApoE-/- mice fed a HFD for 16 weeks prior to weekly 5 
injections of PTL060 for six weeks, atheroma burden was significantly reduced, compared 6 
not only to control mice given either saline or an equimolar dose of parental HLL, but also in 7 
comparison to baseline, indicating that PTL060 caused regression of existing disease. This 8 
was achieved without impacting plasma lipid concentrations. A similar reduction in plaque 9 
burden was seen in mice fed a normal Chow diet. There were significantly fewer CD68+ 10 
macrophages and foam cells present after 6 weeks treatment in the regressing plaques. 11 
In assessing the mechanisms of regression, we considered the importance of inhibiting 12 
vessel wall chemokine gradients. Continuous monocyte recruitment into the vessel wall is 13 
one of the major steps in the pathogenesis of atherosclerosis, as evidenced by studies 14 
showing that simultaneous inhibition of CCL2, CX3CR1 and CCR5 near abolishes 15 
development of atheroma in ApoE-/- mice 36.  In addition, deficiency of MIF also impairs 16 
atheroma development in LDL-R deficient mice 37 an inhibitory anti-MIF antibody has been 17 
shown to prevent atherosclerosis in ApoE-/- mice 38, and our previous work illustrated that 18 
MIF secretion was important. We confirmed that a single dose of PTL060 led to prolonged 19 
suppression of vessel wall MIF (and CCL-2), and that this associated with prevention of 20 
plaque development. In addition, recruitment of labelled CD11b+Ly6G- monocytes, 21 
adoptively transferred 1 week after the last of three doses of PTL060, was reduced by 90%, 22 
compared to that seen in control, saline-treated mice. This is consistent with the idea that 23 
suppression of vessel wall chemokine expression, interrupting the continuous cycle of 24 
monocyte recruitment, foam cell development, cell death and vessel wall inflammation might 25 
be an important contributory mechanism of how PTL060 induces plaque regression.   26 
However, PTL060 also modulated the phenotype of recruited monocytes / macrophages. 27 
Thus, plaque cells in the regressing plaques in PTL060-treated mice had a significantly 28 
 26 
different phenotype compared to those detected in the progressing plaques in control 1 
animals, with reduced expression of pro-inflammatory IFN, TNFα and iNOS, and significant 2 
increases in the proportions of cells expressing CD206, IL-10, ABCA1 and CCR7.  3 
These phenotypic characteristics have all been associated with mechanisms of regression 4 
defined in other studies. For instance after transplantation of atheromatous aorta from ApoE-5 
/- mice into BL/6 mice 39-41, the chemokine receptor CCR7 was shown to be important for 6 
emigration of foam cells, as demonstrated by inhibiting the chemokine ligands for CCR7 42. In 7 
another model, LDLR-/- mice treated with an antisense to miR-33 showed regression 8 
associated with upregulated ABCA1 expression in plaque macrophages and enhanced 9 
reverse cholesterol transport 43, in association with increased levels of circulating HDL, 10 
consistent with the known importance of ABCA1 for cholesterol loading into HDL and with the 11 
phenotype of ABCA1-deficient mice 44. Finally, the importance of polarising new monocyte 12 
recruits to the plaque towards an M2 phenotype has been recently demonstrated in the aortic 13 
transplant model, by confirming that regression is dependent on the expression of both 14 
appropriate chemokine receptors (CCR2/CX3CR1) and the transcription factor STAT6  by 15 
recipient monocytes 45.  16 
These phenotypic changes were evident in newly recruited monocytes, but our adoptive 17 
transfer experiments suggested that CCR2+ or CCR2- monocytes were recruited at different 18 
times following PTL060 treatment. In the first experimental setting, using CD11b+ cells from 19 
CD31-Hir-Tg mice, transferred into ApoE-/- mice fed a HFD for 16 weeks without PTL060 20 
treatment, we showed that CCR2+ monocytes were predominantly recruited, and these 21 
displayed the phenotypic traits associated with regression.  In a second experimental setting, 22 
we showed that the CD11b+ cells recruited after adoptive transfer into mice already treated 23 
with 3 doses of PTL060 were predominantly CCR2- cells but also displaying the same 24 
phenotypic traits associated with regression. In this situation, labelled cells were transferred 25 
one week after the last of three doses of PTL060, into mice in which PTL060 had been 26 
cleared from the circulation, but importantly, into mice in which significant changes in plaque 27 
phenotype had already been induced. We suggest that the differential recruitment of the 28 
 27 
CCR2- (Ly6Clo) subset, known to be precursors of M2 polarised macrophages 46, is most 1 
likely due to the conditions within the plaque already established by the PTL060. We 2 
postulate that, after the first dose, the immediate uptake of PTL060 onto the surface of 3 
circulating CCR2+ monocytes, protects them from thrombin as they are recruited into 4 
established plaques, significantly skews their phenotype as they become macrophages, and 5 
this rapidly establishes the microenvironmental conditions inside the plaque that are required 6 
to initiate regression.  7 
Although the focus of this work has been on the impact of thrombin inhibition on the vessel 8 
wall and circulating leukocytes, they also provide a potential explanation for the mechanisms 9 
through which FXa inhibitors induce regression, though these agents would also influence 10 
signalling through PAR-2, something we’ve not addressed. We also showed immediate 11 
uptake of PTL060 onto circulating platelets after IV injection. Since interactions between 12 
platelets and EC and between platelets and leukocytes, via CD40, have been shown to 13 
promote leukocyte recruitment and exacerbate plaque formation in this model 47, we cannot 14 
exclude the possibility that PTL060 might be modulating these interactions. 15 
However, the data generated showing that weekly adoptive transfer of CD11b+ cells pre-16 
treated with PTL060, or expressing a transgenic hirudin fusion protein can induce the same 17 
degree of regression as systemic PTL060, suggests that protecting plaque-recruited 18 
monocytes from the direct effects of thrombin is the key factor required for regression. Since 19 
thrombin, via protease activated receptor-1 and cullin 3-mediated degradation is known to 20 
promote post-transcriptional downregulation of ABCA1 in macrophages 48, and is also known 21 
to promote M1 polarization of microglia after intracerebral haemorrhage 49, our data is most 22 
consistent with the hypothesis that thrombin plays a hitherto unrecognised but pivotal role in 23 
determining the inflammatory phenotype of plaque macrophages and promoting plaque 24 
progression.  25 
 26 
  27 
 28 
Acknowledgements 1 
We acknowledge the financial support of the King’s Commercialisation Institute.  2 
 3 
Funding Sources. 4 
This work was funded by the Wellcome Trust (award 098300/Z/12/Z).  Additional support 5 
was via the Medical Research Council (MR/P018513/1). 6 
 7 
Disclosures. 8 
None declared 9 
  10 
 29 
References 1 
 2 
1. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. 3 
Arterioscler Thromb Vasc Biol. 2008;28:1897-1908 4 
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J 5 
Med. 2005;352:1685-1695 6 
3. Ross R. Genetically modified mice as models of transplant atherosclerosis. Nat 7 
Med. 1996;2:527-528 8 
4. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur 9 
JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb 10 
Haemost. 1997;78:200-204 11 
5. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, 12 
Badimon L, Nemerson Y, Fuster V, et al. Tissue factor modulates the 13 
thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599 14 
6. Yamashita A, Matsuda S, Matsumoto T, Moriguchi-Goto S, Takahashi M, Sugita C, 15 
Sumi T, Imamura T, Shima M, Kitamura K, et al. Thrombin generation by intimal 16 
tissue factor contributes to thrombus formation on macrophage-rich neointima 17 
but not normal intima of hyperlipidemic rabbits. Atherosclerosis. 2009;206:418-18 
426 19 
7. Weis JR, Pitas RE, Wilson BD, Rodgers GM. Oxidized low-density lipoprotein 20 
increases cultured human endothelial cell tissue factor activity and reduces 21 
protein C activation. FASEB J. 1991;5:2459-2465 22 
8. Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ. Uptake of exogenous free 23 
cholesterol induces upregulation of tissue factor expression in human monocyte-24 
derived macrophages. Proc Natl Acad Sci U S A. 1992;89:10370-10374 25 
 30 
9. Cui MZ, Penn MS, Chisolm GM. Native and oxidized low density lipoprotein 1 
induction of tissue factor gene expression in smooth muscle cells is mediated by 2 
both Egr-1 and Sp1. J Biol Chem. 1999;274:32795-32802 3 
10. Chen D, Weber M, Shiels PG, Dong R, Webster Z, McVey JH, Kemball-Cook G, 4 
Tuddenham EG, Lechler RI, Dorling A. Postinjury vascular intimal hyperplasia in 5 
mice is completely inhibited by CD34+ bone marrow-derived progenitor cells 6 
expressing membrane-tethered anticoagulant fusion proteins. J Thromb Haemost. 7 
2006;4:2191-2198 8 
11. Chen D, Xia M, Hayford C, Tham EL, Semik V, Hurst S, Chen Y, Tam HH, Pan J, 9 
Wang Y, et al. Expression of human tissue factor pathway inhibitor on vascular 10 
smooth muscle cells inhibits secretion of macrophage migration inhibitory factor 11 
and attenuates atherosclerosis in ApoE-/- mice. Circulation. 2015;131:1350-1360 12 
12. Karegli J, Melchionna T, Farrar CA, Greenlaw R, Smolarek D, Horsfield C, Charif R, 13 
McVey JH, Dorling A, Sacks SH, et al. Thrombalexins: Cell-Localized Inhibition of 14 
Thrombin and Its Effects in a Model of High-Risk Renal Transplantation. Am J 15 
Transplant. 2017;17:272-280 16 
13. Hamaoui K, Gowers S, Boutelle M, Cook TH, Hanna G, Darzi A, Smith R, Dorling A, 17 
Papalois V. Organ Pretreatment With Cytotopic Endothelial Localizing Peptides to 18 
Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal 19 
Hemoreperfusion Models. Transplantation. 2016;100:e128-e139 20 
14. Manook M, Kwun J, Burghuber C, Samy K, Mulvihill M, Yoon J, Xu H, MacDonald 21 
AL, Freischlag K, Curfman V, et al. Thrombalexin: Use of a Cytotopic 22 
Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized 23 
Model of Kidney Transplantation. Am J Transplant. 2017;17:2055-2064 24 
 31 
15. Chen D, Giannopoulos K, Shiels PG, Webster Z, McVey JH, Kemball-Cook G, 1 
Tuddenham E, Moore M, Lechler R, Dorling A. Inhibition of intravascular 2 
thrombosis in murine endotoxemia by targeted expression of hirudin and tissue 3 
factor pathway inhibitor analogs to activated endothelium. Blood. 4 
2004;104:1344-1349 5 
16. Ignjatovic V. Thrombin clotting time. Methods Mol Biol. 2013;992:131-138 6 
17. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima 7 
formation in heparin cofactor II deficient mice. Blood. 2007;110:4261-4267 8 
18. Borissoff JI, Otten JJ, Heeneman S, Leenders P, van Oerle R, Soehnlein O, Loubele 9 
ST, Hamulyak K, Hackeng TM, Daemen MJ, et al. Genetic and pharmacological 10 
modifications of thrombin formation in apolipoprotein e-deficient mice 11 
determine atherosclerosis severity and atherothrombosis onset in a neutrophil-12 
dependent manner. PLoS One. 2013;8:e55784 13 
19. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus HA, Blessing E. 14 
Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-15 
deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. 16 
Mediators Inflamm. 2011;2011:432080 17 
20. Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, Yagi S, Yamada 18 
H, Soeki T, Wakatsuki T, et al. Rivaroxaban, a novel oral anticoagulant, attenuates 19 
atherosclerotic plaque progression and destabilization in ApoE-deficient mice. 20 
Atherosclerosis. 2015;242:639-646 21 
21. Lee IO, Kratz MT, Schirmer SH, Baumhakel M, Bohm M. The effects of direct 22 
thrombin inhibition with dabigatran on plaque formation and endothelial 23 
function in apolipoprotein E-deficient mice. The Journal of pharmacology and 24 
experimental therapeutics. 2012;343:253-257 25 
 32 
22. Kadoglou NP, Moustardas P, Katsimpoulas M, Kapelouzou A, Kostomitsopoulos N, 1 
Schafer K, Kostakis A, Liapis CD. The beneficial effects of a direct thrombin 2 
inhibitor, dabigatran etexilate, on the development and stability of 3 
atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate 4 
and atherosclerosis. Cardiovasc Drugs Ther. 2012;26:367-374 5 
23. Pingel S, Tiyerili V, Mueller J, Werner N, Nickenig G, Mueller C. Thrombin 6 
inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch 7 
Med Sci. 2014;10:154-160 8 
24. Preusch MR, Ieronimakis N, Wijelath ES, Cabbage S, Ricks J, Bea F, Reyes M, van 9 
Ryn J, Rosenfeld ME. Dabigatran etexilate retards the initiation and progression 10 
of atherosclerotic lesions and inhibits the expression of oncostatin M in 11 
apolipoprotein E-deficient mice. Drug Des Devel Ther. 2015;9:5203-5211 12 
25. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H, 13 
Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may 14 
promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb 15 
Vasc Biol. 2006;26:2787-2792 16 
26. Posthuma JJ, Posma JJN, van Oerle R, Leenders P, van Gorp RH, Jaminon AMG, 17 
Mackman N, Heitmeier S, Schurgers LJ, Ten Cate H, et al. Targeting Coagulation 18 
Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E 19 
Deficient Mice. Sci Rep. 2019;9:3909 20 
27. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz 21 
R, Alings M, Lonn EM, Anand SS, et al. Rivaroxaban with or without Aspirin in 22 
Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-1330 23 
28. Kidd SK, Bonaca MP, Braunwald E, De Ferrari GM, Lewis BS, Merlini PA, Murphy 24 
SA, Scirica BM, White HD, Morrow DA. Universal Classification System Type of 25 
 33 
Incident Myocardial Infarction in Patients With Stable Atherosclerosis: 1 
Observations From Thrombin Receptor Antagonist in Secondary Prevention of 2 
Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50. J Am Heart Assoc. 3 
2016;5 4 
29. Thelen M, Rosen A, Nairn AC, Aderem A. Regulation by phosphorylation of 5 
reversible association of a myristoylated protein kinase C substrate with the 6 
plasma membrane. Nature. 1991;351:320-322 7 
30. Smith RA. Targeting anticomplement agents. Biochem Soc Trans. 2002;30:1037-8 
1041 9 
31. Chen D, Weber M, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling 10 
A. Complete inhibition of acute humoral rejection using regulated expression of 11 
membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant. 12 
2004;4:1958-1963 13 
32. Chen D, Carpenter A, Abrahams J, Chambers RC, Lechler RI, McVey JH, Dorling A. 14 
Protease-activated receptor 1 activation is necessary for monocyte 15 
chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med. 16 
2008;205:1739-1746 17 
33. Li M, Qian M, Kyler K, Xu J. Endothelial-Vascular Smooth Muscle Cells Interactions 18 
in Atherosclerosis. Front Cardiovasc Med. 2018;5:151 19 
34. Yu H, Moran CS, Trollope AF, Woodward L, Kinobe R, Rush CM, Golledge J. 20 
Angiopoietin-2 attenuates angiotensin II-induced aortic aneurysm and 21 
atherosclerosis in apolipoprotein E-deficient mice. Sci Rep. 2016;6:35190 22 
35. Chen D, Li K, Tham EL, Wei LL, Ma N, Dodd PC, Luo Y, Kirchhofer D, McVey JH, 23 
Dorling A. Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits 24 
 34 
Neointimal Hyperplasia After Endoluminal Injury in Mice. Frontiers in 1 
immunology. 2018;9:1517 2 
36. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, 3 
Proudfoot A, Tedgui A, Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 4 
abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes 5 
atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117:1649-1657 6 
37. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, 7 
Metz CN, et al. Macrophage migration inhibitory factor deficiency impairs 8 
atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 9 
2004;109:3149-3153 10 
38. Burger-Kentischer A, Gobel H, Kleemann R, Zernecke A, Bucala R, Leng L, 11 
Finkelmeier D, Geiger G, Schaefer HE, Schober A, et al. Reduction of the aortic 12 
inflammatory response in spontaneous atherosclerosis by blockade of 13 
macrophage migration inhibitory factor (MIF). Atherosclerosis. 2006;184:28-38 14 
39. Feig JE. Regression of atherosclerosis: insights from animal and clinical studies. 15 
Ann Glob Health. 2014;80:13-23 16 
40. Fisher EA. Regression of Atherosclerosis: The Journey From the Liver to the 17 
Plaque and Back. Arterioscler Thromb Vasc Biol. 2016;36:226-235 18 
41. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic 19 
balance. Nat Rev Immunol. 2013;13:709-721 20 
42. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher 21 
EA. Gene expression changes in foam cells and the role of chemokine receptor 22 
CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad 23 
Sci U S A. 2006;103:3781-3786 24 
 35 
43. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, 1 
Rayner AJ, Chang AN, Suarez Y, et al. Antagonism of miR-33 in mice promotes 2 
reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 3 
2011;121:2921-2931 4 
44. Aiello RJ, Brees D, Francone OL. ABCA1-deficient mice: insights into the role of 5 
monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb 6 
Vasc Biol. 2003;23:972-980 7 
45. Rahman K, Vengrenyuk Y, Ramsey SA, Vila NR, Girgis NM, Liu J, Gusarova V, 8 
Gromada J, Weinstock A, Moore KJ, et al. Inflammatory Ly6Chi monocytes and 9 
their conversion to M2 macrophages drive atherosclerosis regression. J Clin 10 
Invest. 2017;127:2904-2915 11 
46. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. 12 
Nat Rev Cardiol. 2010;7:77-86 13 
47. Gerdes N, Seijkens T, Lievens D, Kuijpers MJ, Winkels H, Projahn D, Hartwig H, 14 
Beckers L, Megens RT, Boon L, et al. Platelet CD40 Exacerbates Atherosclerosis by 15 
Transcellular Activation of Endothelial Cells and Leukocytes. Arterioscler Thromb 16 
Vasc Biol. 2016;36:482-490 17 
48. Raghavan S, Singh NK, Mani AM, Rao GN. Protease-activated receptor 1 inhibits 18 
cholesterol efflux and promotes atherogenesis via cullin 3-mediated degradation 19 
of the ABCA1 transporter. J Biol Chem. 2018;293:10574-10589 20 
49. Wan S, Cheng Y, Jin H, Guo D, Hua Y, Keep RF, Xi G. Microglia Activation and 21 
Polarization After Intracerebral Hemorrhage in Mice: the Role of Protease-22 
Activated Receptor-1. Transl Stroke Res. 2016;7:478-487 23 
 24 
 25 
 36 
Table 1: Effect of PTL060 on body mass and plasma lipids in ApoE-/- mice 1 
 2 
Prevention experiments Aortic Tx recipients*- fed HFD 6-14 weeks (n=6 per group) Single injection* – fed HFD 6-12 weeks (n=6 per group) 
 
BL/6 
CD31-TFPI-
Tg 
P value∆ BL/6 CD31-HIr-Tg  
P 
value∆ 
PBS 
HLL 
(5g/g) 
PTL060 
(2.5g/g) 
PTL060 
(5g/g) 
PTL060 
(10g/g) 
P 
value† 
B
o
d
y
 
m
a
s
s
 Age 6 weeks 
18.6±0.27 18.6±0.25 0.99 19.6±0.42 19.6±0.31 0.99 19.0±0.40 19.4±0.22 19.4±0.44 19.4±0.38 19.2±0.24 0.87 
End of Exp. 25.2±1.71 24.6±1.36 0.63 26.8±0.34 25.9±0.77 0.99 32.0±1.63 32.0±0.99 31.4±0.84 29.8±0.35 29.4±0.73 0.36 
Cholesterol (mmol/L) 53.1±3.31 52.9±3.67 0.99 50.1±4.98 50.2±5.77 0.99 51.0±5.56 54.1±5.70 49.3±4.56 50.3±4.36 50.1±5.44 0.97 
Triglycerides (mmol/L) 2.1±0.14 2.0±0.20 0.99 2.0±0.13 2.0±0.14 0.99 2.1±0.31 2.1±0.36 2.2±0.28 2.2±0.27 2.1±0.30 1.00 
HDL(mmol/L) 1.5±0.11 1.5±0.10 0.99 1.6±0.07 1.5±0.08 0.99 1.4±0.28 1.5±0.08 1.6±0.12 1.5±0.09 1.5±0.09 0.92 
LDL (mmol/L) 57.2±2.73 55.2±3.49 0.97 63.9±9.97 61.0±6.28 0.92 55.6±6.64 54.7±4.48 54.1±4.72 51.7±5.89 52.8±5.42 0.99 
    
Regression 
experiments 
 Series 1 HFD 6-28 weeks (n=6 per group) Series 2 HFD 6-28 weeks (n=6 per group) 
 6-week 
old 
Baseline
ø
 PBS
¥
 Tail only 
PTL060 
(10g/g) 
P 
value† 
Baseline
ø
 PBS HLL (5g/g) 
PTL060 
(5g/g) 
PTL060 
(10g/g) 
P 
value† 
B
o
d
y
 
m
a
s
s
 Age 6 weeks - 19.3±0.28 19.6±0.37 19.1±0.15 19.3±0.38 0.74 20.2±0.39 20.1±0.38 20.6±0.07 20.1±0.30 20.3±0.26 0.73 
Age 22 weeks - 30.5±0.58 32.8±0.44 30.4±0.90 32.0±0.81 0.19 31.5±1.34 31.4±0.84 31.1±0.66 31.2±1.00 31.9±0.78 0.85 
End of Exp. - - 33.2±0.31 31.8±0.73 28.7±1.55 0.03 - 32.9±1.19 31.4±0.33 30.2±0.93 29.8±0.59 0.11 
Cholesterol (mmol/L) 10.3±4.6 56.7±6.08 61.5±6.51 61.9±6.35 57.9±3.61 0.88 54.9±6.25 56.9±6.93 54.1±5.39 53.9±6.31 54.3±13.1 0.41 
Triglycerides (mmol/L) 0.36±0.14 2.08±0.15 2.25±0.11 2.49±0.13 2.19±0.16 0.26 2.27±0.28 1.68±0.31 2.21±0.38 2.2±0.33 2.16±0.69 0.86 
HDL(mmol/L) 4.46±1.1 1.54±0.007 1.49±0.06 1.46±0.06 1.56±0.06 0.65 1.61±0.12 1.58±0.11 1.78±0.2 1.6±0.16 1.68±0.38 0.27 
LDL (mmol/L) 14.4±2.8 46.5±3.39 56.1±2.92 57.4±2.57 50.8±2.84 0.07 53.8±3.51 62.7±4.43 63.5±3.55 60.6±6.79 63.3±16.7 0.97 
 3 
HFD; high fat diet. BL/6; C57BL/6J. HLL; hirulog modified to accept the myristoyl tail (NB: HLL 5g is equimolar to PTL060 10g). PBS; 4 
phosphate buffered saline. Exp.; experiment. HDL; high density lipoprotein. LDL; low density lipoprotein. 5 
‘n’ refers to number of animals per group. Samples from each animal were analysed in triplicate. 6 
*In prevention experiments, aortic transplants performed and single injections given to mice aged 8 weeks, 2 weeks after starting HFD. 7 
øBaseline = week 22. Mice in the ‘baseline’ groups were harvested at this timepoint prior to any treatment 8 
¥Treatments given weekly by IV injection for 6 weeks (mice aged 22-28 weeks). 9 
∆ Two way ANOVA for multiple groups 10 
† One way ANOVA for multiple groups (NB: values from 6-week old mice not included in comparisons) 11 
 12 
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 1 
Figure Legends: 2 
Figure 1: Inhibition of TF or thrombin on EC abolishes MIF expression in vascular wall and 3 
prevents formation of atheroma. 4 
A-E. Three colour immunofluorescence images of sections through donor aortas, 6-12 weeks 5 
post-transplantation. Recipients were ApoE-/- mice, fed a high fat diet (HFD) for two weeks 6 
from age 6 weeks, prior to transplantation of aorta from CD31-TFPI-Tg (A,B), CD31-Hir-Tg 7 
(C-D) or C57BL/6 mice (E).  Blue - nuclear stain 4’,6-diamidino-2-phenylindole (DAPI). Red - 8 
anti-hTFPI (A,B), anti-hirudin (Hir-C,D) or anti-CD31 (E). Green - MIF (A,C,E) or CD31 (B,D). 9 
Each panel of three images shows consecutive sections.  10 
F-J – Analysis of atheroma development in whole aorta (F,G,H) and aortic root (H,I,J) after a 11 
HFD for 6 weeks post-transplantation.  F&G: representative Oil Red O-stained en face 12 
preparations of aorta from ApoE-/- mice transplanted with aorta from CD31-TFPI-Tg (F) or 13 
BL/6 (G) mice. The transplanted section is highlighted by arrows. H: Quantitative 14 
assessments show the area occupied by atheroma, assessed at three different sites (as 15 
indicated) as a proportion of the total area (n=6 males each group) in ApoE-/- mice 16 
transplanted with aortas from CD31-TFPI-Tg (white bars) or BL/6 (grey bars) donors. Graphs 17 
show box plots with median with interquartile range (IQR) with whiskers showing upper and 18 
lower limits and outliers indicated as single data points. Means are represented with ‘x’. I&J 19 
Representative light photomicrographs of elastic/van Gieson stained sections from aortic root 20 
of mice transplanted with aortas from CD31-TFPI-Tg (I) or BL/6 (J) mice. 21 
K-O – Analysis of atheroma development in the whole aorta (K, L,M) and aortic root (M, N, 22 
O) after a HFD for 12 weeks post-transplantation. K&L: representative Oil Red O-stained en 23 
face preparations of aorta from ApoE-/- mice transplanted with aorta from CD31-Hir-Tg (K) or 24 
BL/6 (L) mice. The transplanted section is highlighted by arrows. M: Quantitative 25 
assessments show the area occupied by atheroma, assessed at three different sites (as 26 
indicated) as a proportion of the total area (n=6 males each group) in ApoE-/- mice 27 
transplanted with aortas from CD31-Hir-Tg (white bars) or BL/6 (grey bars) donors. Graphs 28 
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show box plots with median with interquartile range (IQR) with whiskers showing upper and 1 
lower limits and outliers indicated as single data points. Means are represented with ‘x’. N&O 2 
representative light photomicrographs of elastic/van Gieson stained sections from aortic root 3 
of mice transplanted with aortas from CD31-Hir-Tg (N) or BL/6 (O) mice. Quantitative 4 
analyses were performed by a member of the team blinded to the mouse strain. 5 
Comparisons of plaque development analysed by repeated measures two way Anova. 6 
Because multiple comparisons were made from these animals, p<0.02 is statistically 7 
significant. 8 
 9 
Figure 2: Impact of IV PTL060. 10 
A&B: Two colour IF images of cross sections through aorta harvested at 6 hours post-IV 11 
injection of 10g/g PTL060 (A) or equimolar (5g/g) HLL (B) stained with isotype control or 12 
RICS2 antibody (which recognises HLL) as indicated. Blue -DAPI. (NB Sections examined at 13 
all other time points showed less evidence of binding by PTL060). 14 
C-E: Flow cytometric assessment of binding to erythrocytes (C), CD11b+ leukocytes (D) and 15 
platelets (gated on CD41+) (E) obtained from mice given either saline control, HLL (2.5g/g), 16 
or PTL060 (5g/g). Graphs show percentage of population binding RICS antibody (left 17 
column) and the geometric mean of the fluorescence intensity of binding (right column).  18 
Samples were taken from mice at the time points post-injection as indicated. n=3 per group. 19 
F&G: Thrombin clotting times (seconds ± SEM) in plasma. Blood was collected into citrated 20 
tubes at the times specified under terminal anaesthesia before spinning at 15000g for 10 21 
minutes to separate out cellular components and plasma. Thrombin times performed by 22 
adding 25U (F) or 50U (G) thrombin to 100 l of plasma and recording time for a fibrin clot to 23 
form. Mice (n=3 per group) injected with PTL060 (5g/g – filled squares) or equimolar dose 24 
of HLL (2.5g/g – circles). Plasma from mice treated with PTL060 was centrifuged for a 25 
further 20 minutes at 10000g, to remove any membrane bound PTL060, before repeating 26 
assessments (open squares).  27 
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H: Graph depicting tail bleeding times in minutes ± SEM at various times after IV injection of 1 
control phosphate buffered saline (open circles), PTL060 10g/g (squares) or equimolar 2 
(5g/g) HLL (closed circles). N=6 per group. Mouse euthanised at 20 minutes if tail still 3 
bleeding. 4 
 5 
Figure 3: IV PTL060 inhibits MIF and prevents atherosclerosis 6 
A: Quantitative impact of PTL060 on MIF expression by endothelium (left axis), represented 7 
as the proportion of CD31+ cells staining for MIF, plotted against time or development of 8 
atheroma (right axis) 4 weeks post injection. Mice (n=6) given either PBS control (white) or 9 
PTL060 10g/g (grey) by IV injection, 2 weeks after starting a HFD and analysed at the time 10 
points indicated. Graphs show box plots with median with interquartile range (IQR) with 11 
whiskers showing upper and lower limits and outliers indicated as single data points. Means 12 
are represented with ‘x’. Comparisons of plaque development analysed by unpaired t test. 13 
P<0.05 is statistically significant. 14 
B&C: Representative light photomicrographs of elastic/van Gieson stained sections from 15 
aortic root of ApoE-/- mice treated with PBS (B) or 10g/g PTL060 (C). 16 
D: Quantitative impact of PTL060 on MIF expression 1-week post injection (left axis), 17 
represented as the proportion of CD31+ cells staining for MIF, or development of atheroma 18 
(right axis) 4 weeks post injection. Mice (n=6) given either PTL060 2.5g/g (white bars), 19 
PTL060 5g/g (grey bars), PTL060 10g/g (striped bars) or HLL 5g/g (diamond bars) by IV 20 
injection, 2 weeks after starting a HFD and analysed at the time points indicated. HLL 5g/g 21 
is equimolar to PTL060 10g/g.  Graphs show box plots with median with interquartile range 22 
(IQR) with whiskers showing upper and lower limits and outliers indicated as single data 23 
points. Means are represented with ‘x’. Comparisons of plaque development analysed by 24 
repeated measures one-way Anova. P<0.05 is statistically significant 25 
 41 
E-H: Representative light photomicrographs of elastic/van Gieson stained sections from 1 
aortic root of ApoE-/- mice treated with PTL060 2.5g/g (E), 5g/g (F), 10g/g (G), or HLL 2 
5g/g (H). 3 
 4 
Figure 4: IV PTL060 causes regression of atherosclerosis 5 
A-D: Representative Oil Red O-stained en face preparations of aorta from ApoE-/- mice fed a 6 
HFD from age of 6-22 weeks (baseline: A), or 6-28 weeks with weekly injections (weeks 23-7 
28) of saline (B), control cytotopic ‘tail’ compound (C) or PTL060 10g/g (D). 8 
E-H: Representative light photomicrographs of elastic/van Gieson stained sections from 9 
aortic root of ApoE-/- mice fed a HFD from age of 6-22 weeks (baseline: E), or 6-28 weeks 10 
with weekly injections (weeks 23-28) of saline (F), control cytotopic ‘tail’ compound (G) or 11 
PTL060 10g/g (E). 12 
I: Quantitative comparison of impact of PTL060 on atheroma formation in mice on HFD aged 13 
6-22 weeks (white bars) or 6-28 weeks with weekly injections (weeks 23-28) of saline (grey 14 
bars), control ‘tail’ compound (striped bars) or PTL060 10g/g (diamond bars). Comparisons 15 
of plaque development analysed by repeated measures two-way Anova. Because multiple 16 
comparisons were made from these animals, p<0.008 is statistically significant. 17 
J-M: Representative Oil Red O-stained en face preparations of aorta from ApoE-/- mice fed a 18 
HFD from age of 6-22 weeks (Baseline: J), or 6-28 weeks with weekly injections (weeks 23-19 
28) of saline (K), control ‘untailed’ HLL (L) or PTL060 10g/g (M). 20 
N-Q: Representative light photomicrographs of elastic/van Gieson stained sections from 21 
aortic root of ApoE-/- mice fed a HFD from age of 6-22 weeks (N), or 6-28 weeks with weekly 22 
injections (weeks 23-28) of saline (O), control untailed HLL (P) or PTL060 10g/g (Q). 23 
R: Quantlitative comparison of impact of PTL060 on atheroma formation in mice on HFD 24 
aged 6-22 weeks (white bars) followed by weekly injections, for 6 weeks of saline (grey 25 
bars), control untailed HLL (striped bars) or PTL060 10g/g (diamond bars). Comparisons of 26 
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plaque development analysed by repeated measures two way Anova. Because multiple 1 
comparisons were made from these animals, p<0.0026 is statistically significant. 2 
S-T: Impact of PTL060 on foam cells in atherosclerosis. Representative light 3 
photomicrographs of elastic/van Gieson stained sections from aortic root (S) with 4 
consecutive sections analysed by two-colour immunofluorescence (T) stained with DAPI 5 
(blue) or anti-CD68 (green). ApoE-/- mice were fed a HFD from age of 6-22 weeks, followed 6 
by weekly injections, for 6 weeks of saline, control untailed HLL or PTL060 10g/g as 7 
indicated. 8 
U: Graphical representations of the % of plaque area staining with Oil Red O (upper panel) 9 
and, in lower panel, the % of area occupied by CD68+ cells (white bars) with the proportion 10 
of those CD68+ cells co-localising with lipid (grey bars).  Each graph is a box plot with 11 
median with interquartile range (IQR) with whiskers showing upper and lower limits and 12 
outliers indicated as single data points. Means are represented with ‘x’. Data is derived from 13 
an assessment of each of the three aortic root plaques from 6 individual mice, from 14 
consecutive sections as illustrated in S&T. Comparisons of plaque development analysed by 15 
repeated measures two-way Anova. Because multiple comparisons were made from these 16 
animals, p<0.0026 is statistically significant. 17 
V-W: Representative Oil Red O-stained en face preparations of aorta from ApoE-/- mice fed 18 
a normal chow diet to the age of 28 weeks, followed by weekly injections, for 6 weeks of 19 
saline (V) or PTL060 10g/g (W). 20 
X-Y: Representative light photomicrographs of elastic/van Gieson stained sections from 21 
aortic root of ApoE-/- mice fed a chow diet age to the age of 28 weeks, followed by weekly 22 
injections, for 6 weeks of saline (X) or PTL060 10g/g (Y). 23 
Z: Quantitative comparison of impact of PTL060 on atheroma formation in mice on chow diet 24 
to for 28 weeks followed by weekly injections, for 6 weeks of saline (white bars) or PTL060 25 
10g/g (grey bars). Comparisons of plaque development analysed by two way Anova. 26 
P<0.05 is statistically significant. 27 
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 1 
Figure 5: Phenotype of plaque cells after PTL060 2 
Three colour immunofluorescence images show confocal microscopic analysis of 3 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 22 weeks 4 
(‘Baseline’ A, K,O) or 6-28 weeks, with mice administered weekly injections of saline (B,L,P), 5 
HLL (C,M,Q), or PTL060 (D,N,R) as indicated between weeks 22-28. Panels show the 6 
plaque expression of CD68 (red) with (green) either MIF (A-D) CCR7 (K-N) or ABCA1 (O-R). 7 
Yellow in overlay image indicates co-localisation. The plaque area is demarcated by the 8 
lumen (L) and the dotted white line. Le= aortic leaflet.   9 
Each panel of images is accompanied by graphical representations of the % of plaque area 10 
staining for the molecule of interest (E-MIF, H-CCR7, S-ABCA1) and the % of plaque area 11 
occupied by CD68+ (F, I, T) and the proportion of CD68+ cells (white bars) and CD68-12 
negative cells (grey bars) co-staining for MIF (G), CCR7 (J), or ABCA1 (U). Each graph is a 13 
box plot with median with interquartile range (IQR) with whiskers showing upper and lower 14 
limits and outliers indicated as single data points. Means are represented with ‘x’. Each is 15 
derived from an assessment of each of the three aortic root plaques from 6-24 individual 16 
mice.   17 
Comparisons of plaque composition analysed by repeated measures two-way Anova. 18 
Because multiple comparisons were made from these animals, p<0.0026 is statistically 19 
significant. 20 
 21 
 22 
Figure 6 – Impact of adoptive transfer of CD11b+ cells expressing tethered thrombin inhibitor 23 
All panels: CD11b cells, harvested from either BL/6 or CD31-Hir-Tg mice were labelled in 24 
vitro with PKH26 (red) and adoptively transferred into ApoE-/- mice fed a HFD between ages 25 
of 6-22 weeks. Aortic roots were collected 48 hours post-injection, for confocal IF analysis of 26 
the phenotype of adoptively transferred cells. Graphs are a box plot with median with 27 
interquartile range (IQR) with whiskers showing upper and lower limits and outliers indicated 28 
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as single data points. Means are represented with ‘x’. Each is derived from an assessment of 1 
at least 3 aortic root plaques from 6-35 individual mice. 2 
A: To illustrate the expression of MIF (green) at baseline age 22 weeks, throughout the 3 
plaque area in a mouse that received BL/6 CD11b+ cells. 4 
B-D: Comparison of the recruitment of CD11b+ cells from BL/6 (B) and CD31-Hir-Tg (C) 5 
mice. Hirudin (green) only seen in cells from CD31-Hir-Tg mice. D illustrates quantitative 6 
assessment of the proportion of plaque area occupied by PKH26+ cells.  7 
E-G: To illustrate expression of Ly6G (green) within the plaque after adoptive transfer of 8 
CD11b+ cells from BL/6 (E) or CD31-HIr-Tg (F) mice. G illustrates quantitative assessment 9 
of the proportion of PKH26+ cells co-expressing Ly6G. 10 
I-J: To illustrate expression of CCR2 (green) within the plaque after adoptive transfer of 11 
CD11b+ cells from BL/6 (H) or CD31-HIr-Tg (I) mice. J illustrates quantitative assessment of 12 
the proportion of PKH26+ cells co-expressing CCR2. 13 
K-M: To illustrate expression of ABCA1 (green) within the plaque after adoptive transfer of 14 
CD11b+ cells from BL/6 (K) or CD31-HIr-Tg (L) mice. M illustrates quantitative assessment 15 
of the proportion of PKH26+ cells co-expressing ABCA1. 16 
N-P: To illustrate expression of CCR7 (green) within the plaque after adoptive transfer of 17 
CD11b+ cells from BL/6 (N) or CD31-HIr-Tg (O) mice. P illustrates quantitative assessment 18 
of the proportion of PKH26+ cells co-expressing CCR7. 19 
Quantitative comparisons analysed by repeated measures two-way Anova. Because multiple 20 
comparisons were made from these animals, p<0.0055 is statistically significant. 21 
 22 
 23 
Figure 7: Monocyte recruitment and phenotype after systemic PTL060. 24 
Confocal microscopic analysis of three colour immunofluorescence images through 25 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 26 weeks, 26 
with mice administered weekly injections of saline or PTL060 as indicated below between 27 
weeks 22-25. 1 week after the last injection, mice were injected with PKH2-labelled CD11b 28 
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cells (green) and aortic roots harvested 48 hours later. Graphs are a box plot with median 1 
with interquartile range (IQR) with whiskers showing upper and lower limits and outliers 2 
indicated as single data points. Means are represented with ‘x’. Each is derived from a 3 
double assessment of each of the three aortic root plaques from 3 individual mice. 4 
A-C: To illustrate the expression of MIF (red) after adoptive transfer of BL/6 CD11b+ cells in 5 
mice treated with saline (A) or PTL060 (B). C illustrates quantitative assessment of the 6 
proportion of plaque area occupied by PKH2+ cells.  7 
D-F: To illustrate the expression of CCR2 (red) after adoptive transfer of BL/6 CD11b+ cells 8 
in mice treated with saline (D) or PTL060 (E). F illustrates quantitative assessment of the 9 
proportion of PKH2+ cells co-expressing CCR2. 10 
G-I: To illustrate the expression of CCR7 (red) after adoptive transfer of BL/6 CD11b+ cells in 11 
mice treated with saline (G) or PTL060 (H). I illustrates quantitative assessment of the 12 
proportion of PKH2+ cells co-expressing CCR7. 13 
J-K: To illustrate the expression of ABCA1 (red) after adoptive transfer of BL/6 CD11b+ cells 14 
in mice treated with saline (J) or PTL060 (K). L illustrates quantitative assessment of the 15 
proportion of PKH2+ cells co-expressing ABCA1. 16 
Quantitative comparisons analysed by repeated measures two-way Anova. Because multiple 17 
comparisons were made from these animals, p<0.007 is statistically significant 18 
 19 
Figure 8: Regression induced by thrombin inhibitor on isolated CD11b+ cells 20 
Samples represented here are from ApoE-/- mice fed a HFD from age of 6-28 weeks with 21 
weekly (weeks 23-28) injections of CD11b+ cells from BL/6 mice pre-incubated with saline 22 
(A, E), control ‘tail’ molecule (B, F), PTL060 100M (C,G) or with CD11b cells from CD31-23 
Hir-Tg mice (D, H) 24 
A-D: Representative Oil Red O-stained en face preparations of aorta 25 
E-H: Representative light photomicrographs of elastic/van Gieson stained sections from 26 
aortic root  27 
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I: Quantitative comparison of atheroma regression in the whole aorta (en face) or aortic root 1 
of mice fed a HFD from age of 6-28 weeks with weekly (weeks 23-28) injections of CD11b+ 2 
cells from BL/6 mice pre-incubated with saline (white bars), control ‘tail’ molecule (grey bars), 3 
PTL060 100M (striped bars) or with CD11b cells from CD31-Hir-Tg mice (diamond bars). 4 
J: Graph is a box plot with median with interquartile range (IQR) with whiskers showing upper 5 
and lower limits and outliers indicated as single data points. Means are represented with ‘x’. 6 
Each is derived from an assessment of at least 3 aortic root plaques from 6-24 individual 7 
mice. It illustrates the proportion of plaque area occupied by cells expressing the various 8 
markers (as indicated on abscissa) from mice receiving CD11b+ cells from BL/6 mice pre-9 
incubated with saline (white bars) or CD31-Hir-Tg mice (grey bars). 10 
Quantitative comparisons in I&J analysed by repeated measures two-way Anova. Because 11 
multiple comparisons were made from these animals, p<0.0055 is statistically significant.  12 
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Supplementary Figure Legends 1 
Suppl Figure 1: Illustration of th in vivo models used in this manuscript. A: aortic 2 
transplantation. B: prevention of atherosclerosis. C: Regression of atherosclerosis. 3 
 4 
Suppl Figure 2: Inhibition of TF or thrombin on EC abolishes CCL2 and MIF expression in 5 
vascular walls 6 
A-C. Three colour immunofluorescence images of sections through donor aortas, 6 weeks 7 
post-transplantation. Recipients were ApoE-/- mice, fed a high fat diet (HFD) for two weeks 8 
from age 6 weeks, prior to transplantation of aorta from BL/6 (A) CD31-TFPI-Tg (B) or CD31-9 
Hir-Tg (C).  Blue - nuclear stain 4’,6-diamidino-2-phenylindole (DAPI). Red - anti-CD31 (A) 10 
anti-hTFPI (B) or anti-hirudin (Hir-C). Green – CCL2. Each panel of three images shows 11 
consecutive sections.  12 
D&E: Three colour IF images of consecutive sections through aortic root, taken 1, 2 or 3 13 
weeks post IV injection of 10g/g of PTL060 (D) or PBS (E).  ApoE-/- mice were commenced 14 
on a high fat diet 2 weeks prior to the injections.  Blue - DAPI. Red - anti-CD31. Green - MIF. 15 
 16 
Suppl Figure 3: PTL060 inhibits thrombin- and PAR-1-mediated chemokine production in 17 
vitro. 18 
In vitro analysis of MIF (A) or CCL2 (B) production by cultured mouse SMCs, following 19 
stimulation by thrombin, with addition of reagents to demonstrate that PTL060 predominantly 20 
inhibits PAR-1 mediated chemokine production. 21 
Comparisons of significance by unpaired 2-tailed students t test. P<0.05 is considered 22 
significant. 23 
Experiment repeated twice. 24 
 25 
 26 
Suppl Figure 4: Systemic inhibition of inflammation by PTL060. 27 
 48 
Plasma TNFα (A), IFN (B), MIF (C) and CCL2 (D) in different groups of ApoE-/- mice, as 1 
indicated on abscissa.  2 
Graphs show box plots with median with interquartile range (IQR) with whiskers showing 3 
upper and lower limits and outliers indicated as single data points. Means are represented 4 
with ‘x’.  Comparisons analysed by repeated measures two way Anova. Because multiple 5 
comparisons were made from these animals, p<0.0026 is statistically significant. 6 
 7 
 8 
Suppl Figure 5: Phenotype of plaque cells induced by PTL060_2 9 
Confocal microscopic analysis of three colour immunofluorescence images through 10 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 22 weeks 11 
(‘Baseline’, all panels) or 6-28 weeks, with mice administered weekly injections of saline, 12 
HLL, or PTL060 as indicated between weeks 22-28. Panels show the plaque expression of 13 
CD68 (red) with (green) either IL-10 (A) IFN (E) or TNFα (I). Yellow in overlay image 14 
indicates co-localisation. The plaque area is demarcated by the lumen (L) and the dotted 15 
white line. Le= aortic leaflet.   16 
Each panel of images is accompanied by graphical representations of the % of plaque area 17 
staining for the molecule of interest (B-IL-10, F-IFN, J-TNF) and the % of plaque area 18 
occupied by CD68+ (C, G, K) and the proportion of CD68+ cells (white bars) and CD68-19 
negative cells (grey bars) co-staining for IL-10 (D), IFN (H), or TNF (L). Each graph is a 20 
box plot with median with interquartile range (IQR) with whiskers showing upper and lower 21 
limits and outliers indicated as single data points. Means are represented with ‘x’. Each is 22 
derived from an assessment of each of the three aortic root plaques from at least 6 individual 23 
mice. Comparisons analysed by repeated measures two-way Anova. Because multiple 24 
comparisons were made from these animals, p<0.0026 is statistically significant. 25 
 26 
Suppl Figure 6: Phenotype of plaque cells induced by PTL060_3 27 
 49 
Confocal microscopic analysis of three colour immunofluorescence images through 1 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 22 weeks 2 
(‘Baseline’, all panels) or 6-28 weeks, with mice administered weekly injections of saline, 3 
HLL, or PTL060 as indicated between weeks 22-28. Panels show the plaque expression of 4 
CD68 (red) with (green) either iNOs (A) or CD206 (E). Yellow in overlay image indicates co-5 
localisation. The plaque area is demarcated by the lumen (L) and the dotted white line. Le= 6 
aortic leaflet.   7 
Each panel of images is accompanied by graphical representations of the % of plaque area 8 
staining for the molecule of interest (B-iNOS, F-CD206) and the % of plaque area occupied 9 
by CD68+ (C, G) and the proportion of CD68+ cells (white bars) and CD68-negative cells 10 
(grey bars) co-staining for iNOS (D) or CD206 (H). Each graph is a box plot with median with 11 
interquartile range (IQR) with whiskers showing upper and lower limits and outliers indicated 12 
as single data points. Means are represented with ‘x’. Each is derived from an assessment of 13 
each of the three aortic root plaques from at least 6 individual mice. Comparisons analysed 14 
by repeated measures two-way Anova. Because multiple comparisons were made from 15 
these animals, p<0.0026 is statistically significant. 16 
 17 
Suppl Figure 7 – Impact of adoptive transfer of CD11b+ cells expressing hirudin_2 18 
All panels: CD11b cells, harvested from either BL/6 or CD31-Hir-Tg mice were labelled in 19 
vitro with PKH26 (red) and adoptively transferred into ApoE-/- mice fed a HFD between ages 20 
of 6-22 weeks. Aortic roots were collected 48 hours post-injection, for confocal IF analysis of 21 
the phenotype of adoptively transferred cells. Graphs are a box plot with median with 22 
interquartile range (IQR) with whiskers showing upper and lower limits and outliers indicated 23 
as single data points. Means are represented with ‘x’. Each is derived from a double 24 
assessment of each of the six aortic root plaques from 6 individual mice. 25 
A-C: To illustrate expression of IFN (green) within the plaque after adoptive transfer of 26 
CD11b+ cells from BL/6 (A) or CD31-HIr-Tg (B) mice. C illustrates quantitative assessment 27 
of the proportion of PKH26+ cells co-expressing IFN. 28 
 50 
D-F: To illustrate expression of IL-10 (green) within the plaque after adoptive transfer of 1 
CD11b+ cells from BL/6 (D) or CD31-HIr-Tg (E) mice. F illustrates quantitative assessment 2 
of the proportion of PKH26+ cells co-expressing IL-10. 3 
G-I: To illustrate expression of iNOS (green) within the plaque after adoptive transfer of 4 
CD11b+ cells from BL/6 (G) or CD31-HIr-Tg (H) mice. I illustrates quantitative assessment of 5 
the proportion of PKH26+ cells co-expressing iNOS. 6 
J-L: To illustrate expression of CD206 (green) within the plaque after adoptive transfer of 7 
CD11b+ cells from BL/6 (J) or CD31-HIr-Tg (K) mice. L illustrates quantitative assessment of 8 
the proportion of PKH26+ cells co-expressing CD206. 9 
Quantitative comparisons analysed by repeated measures two-way Anova. Because multiple 10 
comparisons were made from these animals, p<0.0055 is statistically significant. 11 
 12 
Suppl Figure 8: Monocyte recruitment and phenotype after systemic PTL060_2. 13 
Confocal microscopic analysis of three colour immunofluorescence images through 14 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 26 weeks, 15 
with mice administered weekly injections of saline or PTL060 as indicated below between 16 
weeks 22-25. 1 week after the last injection, mice were injected with PKH2-labelled CD11b 17 
cells (green) and aortic roots harvested 48 hours later. Graphs are a box plot with median 18 
with interquartile range (IQR) with whiskers showing upper and lower limits and outliers 19 
indicated as single data points. Means are represented with ‘x’. Each is derived from a 20 
double assessment of each of the three aortic root plaques from 3 individual mice. 21 
A-C: To illustrate the expression of IL-10 (red) at adoptive transfer of BL/6 CD11b+ cells in 22 
mice treated with saline (A) or PTL060 (B). C illustrates quantitative assessment of the 23 
proportion of PKH2+ cells co-expressing IL-10.  24 
D-F: To illustrate the expression of TNFα (red) at adoptive transfer of BL/6 CD11b+ cells in 25 
mice treated with saline (D) or PTL060 (E). F illustrates quantitative assessment of the 26 
proportion of PKH2+ cells co-expressing TNFα. 27 
 51 
G-I: To illustrate the expression of IFN (red) at adoptive transfer of BL/6 CD11b+ cells in 1 
mice treated with saline (G) or PTL060 (H). I illustrates quantitative assessment of the 2 
proportion of PKH2+ cells co-expressing IFN. 3 
Quantitative comparisons analysed by repeated measures two-way Anova. Because multiple 4 
comparisons were made from these animals, p<0.007 is statistically significant. 5 
 6 
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Figure 1: Inhibition of TF or thrombin on EC abolishes MIF expression in vascular wall and prevents 
formation of atheroma.
A-E. Three colour immunofluorescence images of sections through donor aortas, 6-12 weeks post-
transplantation. Recipients were ApoE-/- mice, fed a high fat diet (HFD) for two weeks from age 6 weeks, 
prior to transplantation of aorta from CD31-TFPI-Tg (A,B), CD31-Hir-Tg (C-D) or C57BL/6 mice (E).  Blue -
nuclear stain 4’,6-diamidino-2-phenylindole (DAPI). Red - anti-hTFPI (A,B), anti-hirudin (Hir-C,D) or anti-
CD31 (E). Green - MIF (A,C,E) or CD31 (B,D). Each panel of three images shows consecutive sections. 
F-J – Analysis of atheroma development in whole aorta (F,G,H) and aortic root (H,I,J) after a HFD for 6 
weeks post-transplantation.  F&G: representative Oil Red O-stained en face preparations of aorta from 
ApoE-/- mice transplanted with aorta from CD31-TFPI-Tg (F) or BL/6 (G) mice. The transplanted section is 
highlighted by arrows. H: Quantitative assessments show the area occupied by atheroma, assessed at 
three different sites (as indicated) as a proportion of the total area (n=6 males each group) in ApoE-/- mice 
transplanted with aortas from CD31-TFPI-Tg (white bars) or BL/6 (grey bars) donors. Graphs show box 
plots with median with interquartile range (IQR) with whiskers showing upper and lower limits and 
outliers indicated as single data points. Means are represented with ‘x’. I&J Representative light 
photomicrographs of elastic/van Gieson stained sections from aortic root of mice transplanted with aortas 
from CD31-TFPI-Tg (I) or BL/6 (J) mice.
K-O – Analysis of atheroma development in the whole aorta (K, L,M) and aortic root (M, N, O) after a HFD 
for 12 weeks post-transplantation. K&L: representative Oil Red O-stained en face preparations of aorta 
from ApoE-/- mice transplanted with aorta from CD31-Hir-Tg (K) or BL/6 (L) mice. The transplanted section 
is highlighted by arrows. M: Quantitative assessments show the area occupied by atheroma, assessed at 
three different sites (as indicated) as a proportion of the total area (n=6 males each group) in ApoE-/- mice 
transplanted with aortas from CD31-Hir-Tg (white bars) or BL/6 (grey bars) donors. Graphs show box plots 
with median with interquartile range (IQR) with whiskers showing upper and lower limits and outliers 
indicated as single data points. Means are represented with ‘x’. N&O representative light 
photomicrographs of elastic/van Gieson stained sections from aortic root of mice transplanted with aortas 
from CD31-Hir-Tg (N) or BL/6 (O) mice. 
Quantitative analyses were performed by a member of the team blinded to the mouse strain. 
Comparisons of plaque development analysed by repeated measures two way Anova. Because multiple 
comparisons were made from these animals, p<0.02 is statistically significant. 
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Figure 2: Impact of IV PTL060.
A&B: Two colour IF images of cross sections through aorta harvested at 6 hours post-IV injection of 10µg/g 
PTL060 (A) or equimolar (5µg/g) HLL (B) stained with isotype control or RICS2 antibody (which recognises 
HLL) as indicated. Blue -DAPI. (NB Sections examined at all other time points showed less evidence of 
binding by PTL060).
C-E: Flow cytometric assessment of binding to erythrocytes (C), CD11b+ leukocytes (D) and platelets 
(gated on CD41+) (E) obtained from mice given either saline control, HLL (2.5µg/g), or PTL060 (5µg/g). 
Graphs show percentage of population binding RICS antibody (left column) and the geometric mean of the 
fluorescence intensity of binding (right column).  Samples were taken from mice at the time points post-
injection as indicated. n=3 per group.
F&G: Thrombin clotting times (seconds ± SEM) in plasma. Blood was collected into citrated tubes at the 
times specified under terminal anaesthesia before spinning at 15000g for 10 minutes to separate out 
cellular components and plasma. Thrombin times performed by adding 25U (F) or 50U (G) thrombin to 
100 µl of plasma and recording time for a fibrin clot to form. Mice (n=3 per group) injected with PTL060 
(5µg/g – filled squares) or equimolar dose of HLL (2.5µg/g – circles). Plasma from mice treated with 
PTL060 was centrifuged for a further 20 minutes at 10000g, to remove any membrane bound PTL060, 
before repeating assessments (open squares). n=3 per group.
H: Graph depicting tail bleeding times in minutes ± SEM at various times after IV injection of control 
phosphate buffered saline (open circles), PTL060 10µg/g (squares) or equimolar (5µg/g ) HLL (closed 
circles). N=6 per group. Mouse euthanised at 20 minutes if tail still bleeding. 
Figure 3: IV PTL060 inhibits MIF and prevents atherosclerosis
A: Quantitative impact of PTL060 on MIF expression by endothelium (left axis), represented as the 
proportion of CD31+ cells staining for MIF, plotted against time or development of atheroma (right axis) 4 
weeks post injection. Mice (n=6) given either PBS control (white) or PTL060 10µg/g (grey) by IV injection, 2 
weeks after starting a HFD and analysed at the time points indicated. Graphs show box plots with median 
with interquartile range (IQR) with whiskers showing upper and lower limits and outliers indicated as 
single data points. Means are represented with ‘x’. Comparisons of plaque development analysed by 
unpaired t test. P<0.05 is statistically significant.
B&C: Representative light photomicrographs of elastic/van Gieson stained sections from aortic root of 
ApoE-/- mice treated with PBS (B) or 10µg/g PTL060 (C).
D: Quantitative impact of PTL060 on MIF expression 1-week post injection (left axis), represented as the 
proportion of CD31+ cells staining for MIF, or development of atheroma (right axis) 4 weeks post injection. 
Mice (n=6) given either PTL060 2.5µg/g (white bars), PTL060 5µg/g (grey bars), PTL060 10µg/g (striped 
bars) or HLL 5µg/g (diamond bars) by IV injection, 2 weeks after starting a HFD and analysed at the time 
points indicated. HLL 5µg/g is equimolar to PTL060 10µg/g.  Graphs show box plots with median with 
interquartile range (IQR) with whiskers showing upper and lower limits and outliers indicated as single 
data points. Means are represented with ‘x’. Comparisons of plaque development analysed by repeated 
measures one-way Anova. P<0.05 is statistically significant.
E-H: Representative light photomicrographs of elastic/van Gieson stained sections from aortic root of 
ApoE-/- mice treated with PTL060 2.5µg/g (E), 5µg/g (F), 10µg/g (G), or HLL 5µg/g (H). 
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Figure 4: IV PTL060 causes regression of atherosclerosis
A-D: Representative Oil Red O-stained en face preparations of aorta from ApoE-/- mice fed a HFD from age 
of 6-22 weeks (baseline: A), or 6-28 weeks with weekly injections (weeks 23-28) of saline (B), control 
cytotopic ‘tail’ compound (C) or PTL060 10µg/g (D).
E-H: Representative light photomicrographs of elastic/van Gieson stained sections from aortic root of 
ApoE-/- mice fed a HFD from age of 6-22 weeks (baseline: E), or 6-28 weeks with weekly injections (weeks 
23-28) of saline (F), control cytotopic ‘tail’ compound (G) or PTL060 10µg/g (E).
I: Quantative comparison of impact of PTL060 on atheroma formation in mice on HFD aged 6-22 weeks 
(white bars) or 6-28 weeks with weekly injections (weeks 23-28) of saline (grey bars), control ‘tail’ 
compound (striped bars) or PTL060 10µg/g (diamond bars). Comparisons of plaque development analysed 
by repeated measures two way Anova. Because multiple comparisons were made from these animals, 
p<0.008 is statistically significant.
J-M: Representative Oil Red O-stained en face preparations of aorta from ApoE-/- mice fed a HFD from age 
of 6-22 weeks (Baseline: J), or 6-28 weeks with weekly injections (weeks 23-28) of saline (K), control 
‘untailed’ HLL (L) or PTL060 10µg/g (M).
N-Q: Representative light photomicrographs of elastic/van Gieson stained sections from aortic root of 
ApoE-/- mice fed a HFD from age of 6-22 weeks (N), or 6-28 weeks with weekly injections (weeks 23-28) of 
saline (O), control untailed HLL (P) or PTL060 10µg/g (Q).
R: Quantative comparison of impact of PTL060 on atheroma formation in mice on HFD aged 6-22 weeks 
(white bars) followed by weekly injections, for 6 weeks of saline (grey bars), control untailed HLL (striped 
bars) or PTL060 10µg/g (diamond bars). Comparisons of plaque development analysed by repeated 
measures two way Anova. Because multiple comparisons were made from these animals, p<0.0026 is 
statistically significant.
S-T: Impact of PTL060 on foam cells in atherosclerosis. Representative light photomicrographs of 
elastic/van Gieson stained sections from aortic root (S) with consecutive sections analysed by two-colour 
immunofluorescence (T) stained with DAPI (blue) or anti-CD68 (green). ApoE-/- mice were fed a HFD from 
age of 6-22 weeks, followed by weekly injections, for 6 weeks of saline, control untailed HLL or PTL060 
10µg/g as indicated.
U: Graphical representations of the % of plaque area staining with Oil Red O (upper panel) and, in lower 
panel, the % of area occupied by CD68+ cells (white bars) with the proportion of those CD68+ cells co-
localising with lipid (grey bars).  Each graph is a box plot with median with interquartile range (IQR) with 
whiskers showing upper and lower limits and outliers indicated as single data points. Means are 
represented with ‘x’. Data is derived from an assessment of each of the three aortic root plaques from 6 
individual mice, from consecutive sections as illustrated in S&T. Comparisons of plaque development 
analysed by repeated measures two way Anova. Because multiple comparisons were made from these 
animals, p<0.0026 is statistically significant.
V-W: Representative Oil Red O-stained en face preparations of aorta from ApoE-/- mice fed a normal chow 
diet to the age of 28 weeks, followed by weekly injections, for 6 weeks of saline (V) or PTL060 10µg/g (W).
X-Y: Representative light photomicrographs of elastic/van Gieson stained sections from aortic root of 
ApoE-/- mice fed a chow diet age to the age of 28 weeks, followed by weekly injections, for 6 weeks of 
saline (X) or PTL060 10µg/g (Y).
Z: Quantative comparison of impact of PTL060 on atheroma formation in mice on chow diet to for 28 
weeks followed by weekly injections, for 6 weeks of saline (white bars) or PTL060 10µg/g (grey bars). 
Comparisons of plaque development analysed by two way Anova. P<0.05 is statistically significant.
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Figure 5: Phenotype of plaque cells after PTL060
Three colour immunofluorescence images show confocal microscopic analysis of 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 22 weeks 
(‘Baseline’ A, K,O) or 6-28 weeks, with mice administered weekly injections of saline (B,L,P), 
HLL (C,M,Q), or PTL060 (D,N,R) as indicated between weeks 22-28. Panels show the plaque 
expression of CD68 (red) with (green) either MIF (A-D) CCR7 (K-N) or ABCA1 (O-R). Yellow in 
overlay image indicates co-localisation. The plaque area is demarcated by the lumen (L) and 
the dotted white line. Le= aortic leaflet.  
Each panel of images is accompanied by graphical representations of the % of plaque area 
staining for the molecule of interest (E-MIF, H-CCR7, S-ABCA1) and the % of plaque area 
occupied by CD68+ (F, I, T) and the proportion of CD68+ cells (white bars) and CD68-
negative cells (grey bars) co-staining for MIF (G), CCR7 (J), or ABCA1 (U). Each graph is a box 
plot with median with interquartile range (IQR) with whiskers showing upper and lower 
limits and outliers indicated as single data points. Means are represented with ‘x’. Each is 
derived from an assessment of each of the three aortic root plaques from 6-24 individual 
mice. 
Comparisons of plaque composition  analysed by repeated measures two way Anova. 
Because multiple comparisons were made from these animals, p<0.0026 is statistically 
significant.
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Figure 6 – Impact of adoptive transfer of CD11b+ cells expressing tethered thrombin inhibitor
All panels: CD11b cells, harvested from either BL/6 or CD31-Hir-Tg mice were labelled in vitro with PKH26 
(red) and adoptively transferred into ApoE-/- mice fed a HFD between ages of 6-22 weeks. Aortic roots 
were collected 48 hours post-injection, for confocal IF analysis of the phenotype of adoptively transferred 
cells. Graphs are a box plot with median with interquartile range (IQR) with whiskers showing upper and 
lower limits and outliers indicated as single data points. Means are represented with ‘x’. Each is derived 
from an assessment of at least 3 aortic root plaques from 6-35 individual mice.
A: To illustrate the expression of MIF (green) at baseline age 22 weeks, throughout the plaque area in a 
mouse that received BL/6 CD11b+ cells.
B-D: Comparison of the recruitment of CD11b+ cells from BL/6 (B) and CD31-Hir-Tg (C) mice. Hirudin 
(green) only seen in cells from CD31-Hir-Tg mice. D illustrates quantitative assessment of the proportion of 
plaque area occupied by PKH26+ cells. 
E-G: To illustrate expression of Ly6G (green) within the plaque after adoptive transfer of CD11b+ cells 
from BL/6 (E) or CD31-HIr-Tg (F) mice. G illustrates quantitative assessment of the proportion of PKH26+ 
cells co-expressing Ly6G.
I-J: To illustrate expression of CCR2 (green) within the plaque after adoptive transfer of CD11b+ cells from 
BL/6 (H) or CD31-HIr-Tg (I) mice. J illustrates quantitative assessment of the proportion of PKH26+ cells co-
expressing CCR2.
K-M: To illustrate expression of ABCA1 (green) within the plaque after adoptive transfer of CD11b+ cells 
from BL/6 (K) or CD31-HIr-Tg (L) mice. M illustrates quantitative assessment of the proportion of PKH26+ 
cells co-expressing ABCA1.
N-P: To illustrate expression of CCR7 (green) within the plaque after adoptive transfer of CD11b+ cells 
from BL/6 (N) or CD31-HIr-Tg (O) mice. P illustrates quantitative assessment of the proportion of PKH26+ 
cells co-expressing CCR7.
Quantitative comparisons analysed by repeated measures two way Anova. Because multiple comparisons 
were made from these animals, p<0.0055 is statistically significant.
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Figure 7: Monocyte recruitment and phenotype after systemic PTL060.
Confocal microscopic analysis of three colour immunofluorescence images through consecutive sections of 
aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 26 weeks, with mice administered weekly 
injections of saline or PTL060 as indicated below between weeks 22-25. 1 week after the last injection, 
mice were injected with PKH2-labelled CD11b cells (green) and aortic roots harvested 48 hours later. 
Graphs are a box plot with median with interquartile range (IQR) with whiskers showing upper and lower 
limits and outliers indicated as single data points. Means are represented with ‘x’. Each is derived from a 
double assessment of each of the three aortic root plaques from 3 individual mice.
A-C: To illustrate the expression of MIF (red) after adoptive transfer of BL/6 CD11b+ cells in mice treated 
with saline (A) or PTL060 (B). C illustrates quantitative assessment of the proportion of plaque area 
occupied by PKH2+ cells.  D-F: To illustrate the expression of CCR2 (red) after adoptive transfer of BL/6 
CD11b+ cells in mice treated with saline (D) or PTL060 (E). F illustrates quantitative assessment of the 
proportion of PKH2+ cells co-expressing CCR2.  G-I: To illustrate the expression of CCR7 (red) after 
adoptive transfer of BL/6 CD11b+ cells in mice treated with saline (G) or PTL060 (H). I illustrates 
quantitative assessment of the proportion of PKH2+ cells co-expressing CCR7.  J-K: To illustrate the 
expression of ABCA1 (red) after adoptive transfer of BL/6 CD11b+ cells in mice treated with saline (J) or 
PTL060 (K). L illustrates quantitative assessment of the proportion of PKH2+ cells co-expressing ABCA1. 
Quantitative comparisons analysed by repeated measures two way Anova. Because multiple comparisons 
were made from these animals, p<0.007 is statistically significant
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Figure 8: Regression induced by thrombin inhibitor on isolated CD11b+ cells
Samples represented here are from ApoE-/- mice fed a HFD from age of 6-28 weeks with weekly (weeks 
23-28) injections of CD11b+ cells from BL/6 mice pre-incubated with saline (A, E), control ‘tail’ molecule 
(B, F), PTL060 100µM (C,G) or with CD11b cells from CD31-Hir-Tg mice (D, H)
A-D: Representative Oil Red O-stained en face preparations of aorta
E-H: Representative light photomicrographs of elastic/van Gieson stained sections from aortic root 
I: Quantitative comparison of atheroma regression in the whole aorta (en face) or aortic root of mice fed a 
HFD from age of 6-28 weeks with weekly (weeks 23-28) injections of CD11b+ cells from BL/6 mice pre-
incubated with saline (white bars), control ‘tail’ molecule (grey bars), PTL060 100µM (striped bars) or with 
CD11b cells from CD31-Hir-Tg mice (diamond bars).
J: Graph is a box plot with median with interquartile range (IQR) with whiskers showing upper and lower 
limits and outliers indicated as single data points. Means are represented with ‘x’. Each is derived from an 
assessment of at least 3 aortic root plaques from 6-24 individual mice. It illustrates the proportion of 
plaque area occupied by cells expressing the various markers (as indicated on abscissa) from mice 
receiving CD11b+ cells from BL/6 mice pre-incubated with saline (white bars) or CD31-Hir-Tg mice (grey 
bars). 
Quantitative comparisons in I&J analysed by repeated measures two way Anova. Because multiple 
comparisons were made from these animals, p<0.0055 is statistically significant.
Supplemental Material
Incubation time (minutes)
30 60 120
Control PBS - - 99
25µM PTL060 99 95 96
50 µM PTL060 96 98 92
100 µM PTL060 97 87 80
Supplementary Table 1
% viability within Macrophage Forward Scatter / Side scatter gate, as 
assessed by LIVE /Dead aqua fluorescent dye.
See methods for details
Incubated with
Saline Control tail peptides 
only
PTL060
Mean % viability 97.1 97.1 97.2
SEM 0.16 0.1 0.16
Supplementary Table 2
Viability of adoptively transferred CD11b cells, assessed by trypan blue exclusion, 
after incubation with saline, control tail only peptides (100µM), or PTL060 (100µM) 
for 30 minutes immediately prior to injection. 
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Suppl Figure 2: Inhibition of TF or thrombin on EC abolishes CCL2 and MIF expression in 
vascular walls
A-C. Three colour immunofluorescence images of sections through donor aortas, 6 weeks 
post-transplantation. Recipients were ApoE-/- mice, fed a high fat diet (HFD) for two weeks 
from age 6 weeks, prior to transplantation of aorta from BL/6 (A) CD31-TFPI-Tg (B) or CD31-
Hir-Tg (C).  Blue - nuclear stain 4’,6-diamidino-2-phenylindole (DAPI). Red - anti-CD31 (A) 
anti-hTFPI (B) or anti-hirudin (Hir-C). Green – CCL2. Each panel of three images shows 
consecutive sections. 
D&E: Three colour IF images of consecutive sections through aortic root, taken 1, 2 or 3 
weeks post IV injection of 10µg/g of PTL060 (D) or PBS (E).  ApoE-/- mice were commenced 
on a high fat diet 2 weeks prior to the injections.  Blue - DAPI. Red - anti-CD31. Green - MIF.
Supplementary Figure 3
Suppl Figure 3: PTL060 inhibits thrombin- and PAR-1-mediated chemokine production in 
vitro.
In vitro analysis of MIF (A) or CCL2 (B)  production by cultured mouse SMCs, following 
stimulation by thrombin, with addition of reagents to demonstrate that PTL060 
predominantly inhibits PAR-1 mediated chemokine production. N=3 measures per sample. 
Comparisons of significance by unpaired 2-tailed students t test. P<0.05 is considered 
significant.
Experiment repeated twice.
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Suppl Figure 4: Systemic inhibition of inflammation by PTL060.
Plasma TNFα (A), IFNg (B), MIF (C) and CCL2 (D) in different groups of ApoE-/- mice, as 
indicated on abscissa. 
Graphs show box plots with median with interquartile range (IQR) with whiskers showing 
upper and lower limits and outliers indicated as single data points. Means are represented 
with ‘x’. Comparisons analysed by repeated measures two way Anova. Because multiple 
comparisons were made from these animals, p<0.0026 is statistically significant.
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Suppl Figure 5: Phenotype of plaque cells induced by PTL060_2
Confocal microscopic analysis of three colour immunofluorescence images through 
consecutive sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 22 weeks 
(‘Baseline’, all panels) or 6-28 weeks, with mice administered weekly injections of saline, 
HLL, or PTL060 as indicated between weeks 22-28. Panels show the plaque expression of 
CD68 (red) with (green) either IL-10 (A) IFNg (E) or TNFα (I). Yellow in overlay image 
indicates co-localisation. The plaque area is demarcated by the lumen (L) and the dotted 
white line. Le= aortic leaflet.  
Each panel of images is accompanied by graphical representations of the % of plaque area 
staining for the molecule of interest (B-IL-10, F-IFNg, J-TNF α) and the % of plaque area 
occupied by CD68+ (C, G, K) and the proportion of CD68+ cells (white bars) and CD68-
negative cells (grey bars) co-staining for IL-10 (D), IFNg (H), or TNF α (L). Each graph is a box 
plot with median with interquartile range (IQR) with whiskers showing upper and lower 
limits and outliers indicated as single data points. Means are represented with ‘x’. Each is 
derived from an assessment of each of the three aortic root plaques from at least 6 
individual mice. Comparisons analysed by repeated measures two way Anova. Because 
multiple comparisons were made from these animals, p<0.0026 is statistically significant.
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Figure 6: Phenotype of plaque cells induced by PTL060_3
Confocal microscopic analysis of three colour immunofluorescence images through consecutive 
sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 22 weeks (‘Baseline’, all 
panels) or 6-28 weeks, with mice administered weekly injections of saline, HLL, or PTL060 as 
indicated between weeks 22-28. Panels show the plaque expression of CD68 (red) with (green) 
either iNOs (A) or CD206 (E). Yellow in overlay image indicates co-localisation. The plaque area 
is demarcated by the lumen (L) and the dotted white line. Le= aortic leaflet.  
Each panel of images is accompanied by graphical representations of the % of plaque area 
staining for the molecule of interest (B-iNOS, F-CD206) and the % of plaque area occupied by 
CD68+ (C, G) and the proportion of CD68+ cells (white bars) and CD68-negative cells (grey bars) 
co-staining for iNOS (D) or CD206 (H). Each graph is a box plot with median with interquartile 
range (IQR) with whiskers showing upper and lower limits and outliers indicated as single data 
points. Means are represented with ‘x’. Each is derived from an assessment of each of the three 
aortic root plaques from at least 6 individual mice. Comparisons analysed by repeated measures 
two way Anova. Because multiple comparisons were made from these animals, p<0.0026 is 
statistically significant. 
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Figure 7 – Impact of adoptive transfer of CD11b+ cells expressing hirudin_2
All panels: CD11b cells, harvested from either BL/6 or CD31-Hir-Tg mice were labelled in 
vitro with PKH26 (red) and adoptively transferred into ApoE-/- mice fed a HFD between ages 
of 6-22 weeks. Aortic roots were collected 48 hours post-injection, for confocal IF analysis of 
the phenotype of adoptively transferred cells. Graphs are a box plot with median with 
interquartile range (IQR) with whiskers showing upper and lower limits and outliers 
indicated as single data points. Means are represented with ‘x’. Each is derived from a 
double assessment of each of the six aortic root plaques from 6 individual mice.
A-C: To illustrate expression of IFNg (green) within the plaque after adoptive transfer of 
CD11b+ cells from BL/6 (A) or CD31-HIr-Tg (B) mice. (C) illustrates quantitative assessment 
of the proportion of PKH26+ cells co-expressing IFNg .
D-F: To illustrate expression of IL-10 (green) within the plaque after adoptive transfer of 
CD11b+ cells from BL/6 (D) or CD31-HIr-Tg (E) mice. (F) illustrates quantitative assessment 
of the proportion of PKH26+ cells co-expressing IL-10.
G-I: To illustrate expression of iNOS (green) within the plaque after adoptive transfer of 
CD11b+ cells from BL/6 (G) or CD31-HIr-Tg (H) mice. (I) illustrates quantitative assessment 
of the proportion of PKH26+ cells co-expressing iNOS.
J-L: To illustrate expression of CD206 (green) within the plaque after adoptive transfer of 
CD11b+ cells from BL/6 (J) or CD31-HIr-Tg (K) mice. (L) illustrates quantitative assessment of 
the proportion of PKH26+ cells co-expressing CD206. 
Quantitative comparisons analysed by repeated measures two way Anova. Because multiple 
comparisons were made from these animals, p<0.0055 is statistically significant.
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Figure 8: Monocyte recruitment and phenotype after systemic PTL060_2.
Confocal microscopic analysis of three colour immunofluorescence images through consecutive 
sections of aortic roots of ApoE-/- mice, fed a high fat diet from 6 to 26 weeks, with mice 
administered weekly injections of saline or PTL060 as indicated below between weeks 22-25. 1 
week after the last injection, mice were injected with PKH2-labelled CD11b cells (green) and aortic 
roots harvested 48 hours later. Graphs are a box plot with median with interquartile range (IQR) 
with whiskers showing upper and lower limits and outliers indicated as single data points. Means 
are represented with ‘x’. Each is derived from a double assessment of each of the three aortic root 
plaques from 3 individual mice.
A-C: To illustrate the expression of IL-10 (red) after adoptive transfer of BL/6 CD11b+ cells in mice 
treated with saline (A) or PTL060 (B). (C) illustrates quantitative assessment of the proportion of 
PKH2+ cells co-expressing IL-10. 
D-F: To illustrate the expression of TNFα (red) after adoptive transfer of BL/6 CD11b+ cells in mice 
treated with saline (D) or PTL060 (E). (F) illustrates quantitative assessment of the proportion of 
PKH2+ cells co-expressing TNFα.
G-I: To illustrate the expression of IFNg (red) after adoptive transfer of BL/6 CD11b+ cells in mice 
treated with saline (G) or PTL060 (H). (I) illustrates quantitative assessment of the proportion of 
PKH2+ cells co-expressing IFNg.
Quantitative comparisons analysed by repeated measures two way Anova. Because multiple 
comparisons were made from these animals, p<0.007 is statistically significant.
